EC 2.1.1.* (methyltransferases) inhibitor - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	*EC 2.1.1. (methyltransferases) inhibitor**	go back to main search page
Accession:	CHEBI:76871	browse the term
Definition:	An EC 2.1.* (C1-transferase) inhibitor that interferes with the action of any methyltransferase (EC 2.1.1.*).
Synonyms:	related_synonym:	EC 2.1.1.* (methyltransferases) inhibitors; EC 2.1.1.* inhibitor; EC 2.1.1.* inhibitors; methyltransferase (EC 2.1.1.) inhibitor; methyltransferase (EC 2.1.1.) inhibitors

show annotations for term's descendants Sort by:
Rat (689) Mouse (704) Human (715) Chinchilla (0) Bonobo (0) Dog (0) Squirrel (0) Pig (0) Green Monkey (0) Naked Mole-rat (0) All
Genes (689)

amodiaquine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

multiple interactions

Amodiaquine analog inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]; Amodiaquine inhibits the reaction [Paraoxon results in decreased activity of ACHE protein]

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein
Amodiaquine results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

butyrylcholinesterase

multiple interactions

Amodiaquine inhibits the reaction [Paraoxon results in decreased activity of BCHE protein]

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

Amodiaquine results in decreased expression of BCL2 protein
[Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone morphogenetic protein 6

increases expression

Amodiaquine results in increased expression of BMP6 mRNA

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

caspase 3

increases cleavage

Amodiaquine results in increased cleavage of CASP3 protein

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cyclin D1

affects expression

Amodiaquine affects the expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin-dependent kinase inhibitor 1A

affects expression

Amodiaquine affects the expression of CDKN1A mRNA; Amodiaquine affects the expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cytotoxic T-lymphocyte-associated protein 4

multiple interactions

CTLA4 protein affects the reaction [[PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]; CTLA4 protein affects the reaction [PDCD1 protein affects the reaction [[LY6C1 protein co-treated with LY6G protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]]

NCBI chr 9:62,318,874...62,325,978
Ensembl chr 9:62,319,312...62,324,963

G

cathepsin B

decreases activity

Amodiaquine results in decreased activity of CTSB protein

NCBI chr15:37,389,636...37,410,508
Ensembl chr15:37,389,629...37,410,500

G

cathepsin D

decreases activity

Amodiaquine results in decreased activity of CTSD protein

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cathepsin L

decreases activity

Amodiaquine results in decreased activity of CTSL protein

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cytochrome P450, family 1, subfamily a, polypeptide 1

increases activity
multiple interactions
decreases response to substance
increases metabolic processing

Amodiaquine results in increased activity of CYP1A1 protein
[CYP1A1 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine
CYP1A1 protein results in decreased susceptibility to Amodiaquine

PMID:12451431 PMID:31629065

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity
increases metabolic processing
multiple interactions

Amodiaquine results in decreased activity of CYP1A2 protein
CYP1A2 protein results in increased metabolism of Amodiaquine
[CYP1A2 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine; [Gemfibrozil results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Amodiaquine; [Trimethoprim results in decreased activity of CYP1A2 protein] which results in decreased metabolism of Amodiaquine

PMID:11124226 PMID:26599973 PMID:31629065

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases response to substance
increases metabolic processing
multiple interactions

CYP1B1 protein results in decreased susceptibility to Amodiaquine
CYP1B1 protein results in increased metabolism of Amodiaquine
[CYP1B1 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 2, subfamily a, polypeptide 1

increases metabolic processing
multiple interactions

CYP2A13 protein results in increased metabolism of Amodiaquine
[CYP2A13 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine

NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887

G

cytochrome P450, family 2, subfamily b, polypeptide 3

multiple interactions
increases metabolic processing

[CYP2B6 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, subfamily 2, polypeptide 11

multiple interactions
increases metabolic processing

[CYP2C18 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases activity
increases metabolic processing
multiple interactions

Amodiaquine results in decreased activity of CYP2C19 protein
CYP2C19 protein results in increased metabolism of Amodiaquine
[CYP2C19 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine

PMID:11124226 PMID:31629065

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily c, polypeptide 79

multiple interactions
increases response to substance
increases metabolic processing
affects metabolic processing

[5-bromotryptamine analog results in decreased activity of CYP2C8 protein] which results in decreased metabolism of Amodiaquine; [5-chlorotryptamine analog results in decreased activity of CYP2C8 protein] which results in decreased metabolism of Amodiaquine; [5-fluorotryptamine analog results in decreased activity of CYP2C8 protein] which results in decreased metabolism of Amodiaquine; [CYP2C8 protein results in increased metabolism of Amodiaquine] which results in increased abundance of and results in increased secretion of desethylamodiaquine; [CYP2C8 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine; [CYP2C8 protein results in increased metabolism of Amodiaquine] which results in increased chemical synthesis of amodiaquine quinoneimine; [CYP2C8 protein results in increased metabolism of Amodiaquine] which results in increased chemical synthesis of desethylamodiaquine; [CYP2C8 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK1 protein; [CYP2C8 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK3 protein; [CYP2C8 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK8 protein; [Gemfibrozil co-treated with Amodiaquine] results in decreased activity of CYP2C8 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; [Tryptamines analog results in decreased activity of CYP2C8 protein] which results in decreased metabolism of Amodiaquine; Felodipine inhibits the reaction [CYP2C8 protein results in increased metabolism of Amodiaquine]; Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]
CYP2C8 protein affects the metabolism of Amodiaquine

PMID:12920490 PMID:15155557 PMID:15601807 PMID:15626586 PMID:15771232 More...

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases metabolic processing
multiple interactions

CYP2D6 protein results in increased metabolism of Amodiaquine
[CYP2D6 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine; [CYP2D6 protein results in increased metabolism of Amodiaquine] which results in increased chemical synthesis of amodiaquine quinoneimine

PMID:28478157 PMID:31629065 PMID:33259822

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions
increases metabolic processing

[CYP2E1 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
increases metabolic processing
increases response to substance

[CYP3A4 protein results in increased metabolism of Amodiaquine] which results in increased abundance of and results in increased secretion of desethylamodiaquine; [CYP3A4 protein results in increased metabolism of Amodiaquine] which results in increased chemical synthesis of amodiaquine quinoneimine; [CYP3A4 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK1 protein; [CYP3A4 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK3 protein; [CYP3A4 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK8 protein; [Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]

PMID:28478157 PMID:31629065

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases metabolic processing
multiple interactions

CYP3A5 protein results in increased metabolism of Amodiaquine
[CYP3A5 protein results in increased metabolism of Amodiaquine] which results in increased abundance of desethylamodiaquine

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

E2F transcription factor 1

affects expression

Amodiaquine affects the expression of E2F1 mRNA; Amodiaquine affects the expression of E2F1 protein

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

epiregulin

increases expression

Amodiaquine results in increased expression of EREG mRNA

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

glutamic--pyruvic transaminase

multiple interactions

[LY6C1 protein co-treated with LY6G protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]; [PDCD1 protein co-treated with LAG3 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]; [PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]; CTLA4 protein affects the reaction [[PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]; CTLA4 protein affects the reaction [PDCD1 protein affects the reaction [[LY6C1 protein co-treated with LY6G protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]]; PDCD1 protein affects the reaction [[LY6C1 protein co-treated with LY6G protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

interleukin 1 alpha

decreases expression

Amodiaquine results in decreased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

lymphocyte activating 3

multiple interactions

[PDCD1 protein co-treated with LAG3 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]

NCBI chr 4:157,712,665...157,722,229
Ensembl chr 4:157,712,667...157,720,404

G

mitogen activated protein kinase 1

multiple interactions

[CYP2C8 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK1 protein; [CYP3A4 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[CYP2C8 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK3 protein; [CYP3A4 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

[CYP2C8 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK8 protein; [CYP3A4 protein results in increased susceptibility to Amodiaquine] which results in increased phosphorylation of MAPK8 protein

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

MCL1 apoptosis regulator, BCL2 family member

decreases expression
multiple interactions

Amodiaquine results in decreased expression of MCL1 protein
[Ketoconazole inhibits the reaction [CYP3A4 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

Amodiaquine results in increased expression of MET mRNA

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

myeloperoxidase

affects response to substance

MPO protein affects the susceptibility to Amodiaquine

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

N-ribosyldihydronicotinamide:quinone dehydrogenase 2

multiple interactions

Amodiaquine inhibits the reaction [NQO2 protein results in increased reduction of Vitamin K 3]

NCBI chr17:30,909,482...30,938,725
Ensembl chr17:30,909,187...30,938,320

G

nuclear receptor subfamily 4, group A, member 2

multiple interactions

Amodiaquine binds to and results in increased activity of NR4A2 protein

NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877

G

programmed cell death 1

multiple interactions

[PDCD1 protein co-treated with LAG3 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]; [PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]; CTLA4 protein affects the reaction [[PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]; CTLA4 protein affects the reaction [PDCD1 protein affects the reaction [[LY6C1 protein co-treated with LY6G protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]]; PDCD1 protein affects the reaction [[LY6C1 protein co-treated with LY6G protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]

NCBI chr 9:94,418,786...94,431,945
Ensembl chr 9:94,418,791...94,431,937

G

phosphotyrosine interaction domain containing 1

increases expression

Amodiaquine results in increased expression of PID1 mRNA

NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044

G

prostaglandin-endoperoxide synthase 2

decreases expression

Amodiaquine results in decreased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RB transcriptional corepressor 1

affects phosphorylation

Amodiaquine affects the phosphorylation of RB1 protein

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

transforming growth factor, beta 1

multiple interactions

[PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]; CTLA4 protein affects the reaction [[PDCD1 protein co-treated with TGFB1 protein] affects the reaction [Amodiaquine results in increased expression of GPT protein]]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

TNF alpha induced protein 6

decreases expression

Amodiaquine results in decreased expression of TNFAIP6 mRNA

NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649

G

tumor protein p53

increases activity
affects expression

Amodiaquine results in increased activity of TP53 protein
Amodiaquine affects the expression of TP53 protein

PMID:12082016 PMID:24113242

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

berberine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression

berberine increases expression of abca1 protein in mouse liver and human hepatocytes

RGD

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily B member 1A

increases expression

Berberine results in increased expression of ABCB1A mRNA

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP-binding cassette, sub-family B member 1B

increases expression

Berberine results in increased expression of ABCB1B mRNA

NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199

G

acyl-CoA dehydrogenase medium chain

multiple interactions

Berberine inhibits the reaction [Ethanol results in decreased expression of ACADM mRNA]

NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147

G

aggrecan

decreases expression

Berberine results in decreased expression of ACAN mRNA

NCBI chr 1:132,981,582...133,044,416
Ensembl chr 1:132,981,582...133,043,627

G

acetylcholinesterase

multiple interactions
decreases activity

Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased activity of ACHE protein]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of ACHE mRNA]; Berberine inhibits the reaction [acetamiprid results in increased activity of ACHE protein]
Berberine results in decreased activity of ACHE protein

PMID:29170048 PMID:33844597 PMID:37350525

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

acyl-CoA oxidase 1

multiple interactions

Berberine inhibits the reaction [Ethanol results in decreased expression of ACOX1 mRNA]

NCBI chr10:101,406,197...101,431,252
Ensembl chr10:101,406,197...101,431,232

G

actin alpha 2, smooth muscle

decreases expression
multiple interactions

Berberine results in decreased expression of ACTA2 protein
Berberine inhibits the reaction [Particulate Matter results in increased expression of ACTA2 mRNA]

PMID:17973934 PMID:37839514

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

adiponectin, C1Q and collagen domain containing

multiple interactions

Berberine inhibits the reaction [Clozapine results in increased expression of ADIPOQ mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of ADIPOQ mRNA]

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

advanced glycosylation end product-specific receptor

multiple interactions

Berberine inhibits the reaction [Bortezomib results in increased expression of AGER mRNA]

NCBI chr20:4,148,150...4,151,361
Ensembl chr20:4,147,890...4,151,078

G

aryl hydrocarbon receptor

increases activity

Berberine results in increased activity of AHR protein

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

AKT serine/threonine kinase 1

multiple interactions
decreases phosphorylation
increases phosphorylation

Berberine inhibits the reaction [Glucose results in decreased phosphorylation of AKT1 protein]
Berberine results in decreased phosphorylation of AKT1 protein
Berberine inhibits the reaction [Thioacetamide results in increased phosphorylation of AKT1 protein]
Berberine results in increased phosphorylation of AKT1 protein

PMID:23954465 PMID:30138605 PMID:33325633

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

AKT serine/threonine kinase 2

multiple interactions

Berberine inhibits the reaction [Dexamethasone results in decreased expression of AKT2 mRNA]

NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817

G

albumin

multiple interactions

Berberine inhibits the reaction [Thioacetamide results in decreased expression of ALB protein]

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

amyloid beta precursor protein

multiple interactions

Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of APP mRNA]

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

aurora kinase B

decreases expression

Berberine results in decreased expression of AURKB mRNA

NCBI chr10:53,744,290...53,750,831
Ensembl chr10:53,745,142...53,750,837

G

aurora kinase C

increases expression

Berberine results in increased expression of AURKC mRNA

NCBI chr 1:66,843,653...66,849,775
Ensembl chr 1:66,843,653...66,864,386

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression

[Berberine co-treated with Thioacetamide] results in increased expression of BAX mRNA; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of BAX mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of BAX protein]
Berberine results in increased expression of BAX mRNA; Berberine results in increased expression of BAX protein
[Berberine co-treated with Cisplatin] results in increased expression of BAX protein; [Berberine co-treated with Niacinamide] results in increased expression of BAX protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased expression of BAX protein]; SRT1720 inhibits the reaction [Berberine results in increased expression of BAX protein]

PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 More...

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

Bcl-2 binding component 3

increases expression
multiple interactions

Berberine results in increased expression of BBC3 mRNA
[Berberine co-treated with Niacinamide] results in increased expression of BBC3 mRNA

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

decreases expression
increases expression
multiple interactions

Berberine results in decreased expression of BCL2 mRNA; Berberine results in decreased expression of BCL2 protein
Berberine results in increased expression of BCL2 protein
Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of BCL2 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of BCL2 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of BCL2 mRNA]
[Berberine co-treated with Cisplatin] results in decreased expression of BCL2 protein; [Berberine co-treated with Niacinamide] results in decreased expression of BCL2 protein; Berberine inhibits the reaction [Glucose results in decreased expression of BCL2 protein]

PMID:16505103 PMID:20656010 PMID:23954465 PMID:24751971 PMID:25600690 More...

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

decreases expression

Berberine results in decreased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479

G

Bcl2-like 11

multiple interactions
increases expression

[Berberine co-treated with Niacinamide] results in increased expression of BCL2L11 mRNA
Berberine results in increased expression of BCL2L11 mRNA

NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068

G

beclin 1

multiple interactions

Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of BECN1 mRNA]
Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BECN1 protein]

PMID:35439518 PMID:38705399

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

bone gamma-carboxyglutamate protein

increases expression
multiple interactions

Berberine results in increased expression of BGLAP mRNA; Berberine results in increased expression of BGLAP protein
CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein]

NCBI chr 2:173,838,518...173,839,495
Ensembl chr 2:173,838,518...173,839,495

G

baculoviral IAP repeat-containing 5

affects binding

Berberine binds to BIRC5 promoter

NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380

G

BCL2 interacting protein 3

multiple interactions
increases expression

[Cisplatin co-treated with Berberine] results in increased expression of BNIP3 protein
Berberine promotes the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of BNIP3 protein]
Berberine results in increased expression of BNIP3 protein

PMID:36070022 PMID:38705399

NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359

G

BCL2 interacting protein 3 like

increases expression
multiple interactions

Berberine results in increased expression of BNIP3L protein
[Cisplatin co-treated with Berberine] results in increased expression of BNIP3L protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]

NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803

G

caspase 1

multiple interactions

Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of and results in increased cleavage of CASP1 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CASP1 mRNA]

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

multiple interactions
increases activity
increases cleavage
increases expression

[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of CASP3 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of CASP3 protein]; Berberine results in increased cleavage of and results in increased activity of CASP3 protein
Berberine inhibits the reaction [Particulate Matter results in increased expression of CASP3 protein]
Berberine increases activity of CASP3 protein in colon epithelial cells
Berberine results in increased cleavage of CASP3 protein
[Berberine co-treated with Thioacetamide] results in increased expression of CASP3 mRNA; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of CASP3 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased activity of CASP3 protein]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of CASP3 mRNA]
Berberine results in increased activity of CASP3 protein
Berberine results in increased expression of CASP3 mRNA

CTD
RGD

PMID:16505103 PMID:20656010 PMID:25600690 PMID:26712469 PMID:30138605 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

increases activity

Berberine results in increased activity of CASP8 protein

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

caspase 9

increases cleavage
multiple interactions

Berberine results in increased cleavage of CASP9 protein
Berberine inhibits the reaction [Particulate Matter results in increased expression of CASP9 protein]
[Berberine co-treated with Thioacetamide] results in increased expression of CASP9 mRNA
[Berberine co-treated with Niacinamide] results in increased cleavage of CASP9 protein

PMID:16505103 PMID:26712469 PMID:30138605 PMID:37839514

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

catalase

multiple interactions

Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the activity of CAT protein]; Berberine inhibits the reaction [acetamiprid results in decreased activity of CAT protein]; Berberine inhibits the reaction [Bortezomib results in decreased expression of CAT protein]; Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of CAT protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of CAT protein]; Berberine inhibits the reaction [Thioacetamide results in decreased activity of CAT protein]
Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in decreased expression of CAT protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of CAT protein]

PMID:20828602 PMID:24751971 PMID:25600690 PMID:30138605 PMID:33460233 More...

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

multiple interactions

Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]
Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of CCL2 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CCL2 mRNA]

PMID:16391493 PMID:35691465 PMID:38705399

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin D1

decreases expression
multiple interactions

Berberine results in decreased expression of CCND1 protein
Berberine inhibits the reaction [CDK4 mRNA binds to CCND1 mRNA]

PMID:16505103 PMID:33325633 PMID:36822301

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin D2

decreases expression

Berberine results in decreased expression of CCND2 protein

NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495

G

cyclin E1

decreases expression

Berberine results in decreased expression of CCNE1 protein

NCBI chr 1:90,781,947...90,791,188
Ensembl chr 1:90,781,949...90,791,101

G

cyclin T1

multiple interactions

Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CCNT1 protein]

NCBI chr 7:129,687,146...129,718,080
Ensembl chr 7:129,691,209...129,717,871

G

CD36 molecule

increases expression
multiple interactions

Berberine results in increased expression of CD36 mRNA
Berberine results in increased expression of CD36 mRNA; Berberine results in increased expression of CD36 protein
15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of CD36 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased expression of CD36 protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of CD36 mRNA]; Berberine results in increased expression of and affects the localization of CD36 protein; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA]

PMID:28038998 PMID:29408570

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cadherin 1

multiple interactions

Berberine inhibits the reaction [Particulate Matter results in decreased expression of CDH1 mRNA]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cadherin 2

decreases expression

Berberine results in decreased expression of CDH2 mRNA

NCBI chr18:7,776,704...7,990,934
Ensembl chr18:7,776,704...7,990,167

G

cyclin dependent kinase 2

decreases expression

Berberine results in decreased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

decreases expression
multiple interactions

Berberine results in decreased expression of CDK4 protein
Berberine inhibits the reaction [CDK4 mRNA binds to CCND1 mRNA]

PMID:16505103 PMID:36822301

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin-dependent kinase 6

decreases expression

Berberine results in decreased expression of CDK6 protein

NCBI chr 4:30,637,650...30,829,688
Ensembl chr 4:30,646,460...30,829,634

G

cyclin-dependent kinase 9

multiple interactions

Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 mRNA]; Berberine affects the reaction [[Streptozocin co-treated with Dietary Carbohydrates co-treated with Dietary Fats] affects the expression of CDK9 protein]

NCBI chr 3:15,996,467...16,001,315
Ensembl chr 3:15,996,468...16,002,410

G

cyclin-dependent kinase inhibitor 1A

increases expression

Berberine results in increased expression of CDKN1A protein

PMID:16505103 PMID:23747414

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 1B

increases expression

Berberine results in increased expression of CDKN1B protein

NCBI chr 4:167,760,067...167,765,177
Ensembl chr 4:167,760,181...167,764,982

G

cyclin-dependent kinase inhibitor 1C

increases expression

Berberine results in increased expression of CDKN1C mRNA

NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048

G

CCAAT/enhancer binding protein alpha

multiple interactions
decreases expression

Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of CEBPA protein]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of CEBPA protein]
Berberine results in decreased expression of CEBPA mRNA; Berberine results in decreased expression of CEBPA protein

PMID:20564506 PMID:26478571 PMID:37511356

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CCAAT/enhancer binding protein beta

affects phosphorylation
multiple interactions
increases expression

Berberine affects the phosphorylation of CEBPB protein
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Berberine results in increased phosphorylation of CEBPB protein]; CEBPB protein promotes the reaction [Berberine results in increased expression of CD36 mRNA]
Berberine results in increased expression of CEBPB mRNA

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

checkpoint kinase 1

increases expression

Berberine results in increased expression of CHEK1 protein modified form

NCBI chr 8:36,420,565...36,443,477
Ensembl chr 8:36,420,569...36,441,009

G

checkpoint kinase 2

increases expression

Berberine results in increased expression of CHEK2 protein modified form

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

collagen type X alpha 1 chain

increases expression

Berberine results in increased expression of COL10A1 mRNA

NCBI chr20:38,183,103...38,189,488
Ensembl chr20:38,182,494...38,189,494

G

collagen type I alpha 1 chain

increases expression
multiple interactions

Berberine results in increased expression of COL1A1 mRNA
Berberine inhibits the reaction [Particulate Matter results in increased expression of COL1A1 mRNA]

PMID:26478571 PMID:37839514

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type II alpha 1 chain

decreases expression

Berberine results in decreased expression of COL2A1 mRNA

NCBI chr 7:129,098,489...129,127,560
Ensembl chr 7:129,098,786...129,127,546

G

collagen type III alpha 1 chain

multiple interactions

Berberine inhibits the reaction [Particulate Matter results in increased expression of COL3A1 mRNA]

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

cytochrome c oxidase subunit 4i1

multiple interactions

Berberine inhibits the reaction [acetamiprid results in decreased expression of COX4I1 mRNA]

NCBI chr19:48,721,680...48,727,920
Ensembl chr19:48,721,199...48,727,921

G

carnitine palmitoyltransferase 1A

multiple interactions

Berberine inhibits the reaction [Ethanol results in decreased expression of CPT1A mRNA]

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cAMP responsive element binding protein 1

multiple interactions

Berberine inhibits the reaction [Bortezomib results in decreased expression of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

CREB binding protein

increases expression

Berberine results in increased expression of CREBBP mRNA

NCBI chr10:11,335,551...11,461,888
Ensembl chr10:11,335,953...11,461,888

G

cystatin C

multiple interactions

Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of CST3 protein]

NCBI chr 3:136,336,923...136,340,796
Ensembl chr 3:136,336,920...136,340,822

G

catenin beta 1

increases expression
multiple interactions

Berberine results in increased expression of CTNNB1 protein
CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of BGLAP protein]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein]

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin D

multiple interactions
decreases cleavage

GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSD protein]

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cathepsin L

decreases cleavage
multiple interactions

Berberine results in decreased cleavage of CTSL protein
Acetylcysteine inhibits the reaction [Berberine results in decreased cleavage of CTSL protein]; GSK2795039 affects the reaction [Berberine results in decreased cleavage of CTSL protein]

NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548

G

cytochrome b-245 beta chain

multiple interactions

Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein]

NCBI chr X:13,358,101...13,392,570
Ensembl chr X:13,359,430...13,392,586

G

cytochrome c, somatic

affects localization
multiple interactions

Berberine affects the localization of CYCS protein
[Berberine co-treated with Cisplatin] results in increased expression of CYCS protein

PMID:16505103 PMID:36070022

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 17, subfamily a, polypeptide 1

multiple interactions

Berberine inhibits the reaction [Dexamethasone results in increased expression of CYP17A1 mRNA]

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity
increases expression
multiple interactions

Berberine results in decreased activity of CYP1A1 protein
Berberine results in increased expression of CYP1A1 mRNA
Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A1 mRNA]

PMID:16046213 PMID:22342832 PMID:24583342

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

Berberine inhibits the reaction [beta-Naphthoflavone results in increased expression of CYP1A2 mRNA]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases expression
multiple interactions

Berberine results in increased expression of CYP2B10 mRNA
Berberine inhibits the reaction [Streptozocin results in increased expression of CYP2B10 mRNA]; Berberine promotes the reaction [Phenobarbital results in increased expression of CYP2B10 mRNA]

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases expression
multiple interactions

Berberine results in decreased expression of CYP2E1 mRNA
Berberine inhibits the reaction [Ethanol results in increased expression of CYP2E1 protein]; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA]

PMID:22342832 PMID:25455889

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

decreases expression
multiple interactions
decreases activity

Berberine results in decreased expression of CYP3A4 mRNA; Berberine results in decreased expression of CYP3A4 protein
[Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA
Berberine results in decreased activity of CYP3A4 protein
Atorvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 mRNA]; Berberine promotes the reaction [Atorvastatin results in decreased expression of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of CYP3A4 protein]; Berberine promotes the reaction [Simvastatin results in decreased expression of CYP3A4 protein]; Simvastatin promotes the reaction [Berberine results in decreased activity of CYP3A4 protein]

PMID:21524698 PMID:30086269

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

dickkopf WNT signaling pathway inhibitor 1

multiple interactions

DKK1 protein inhibits the reaction [Berberine results in increased expression of BGLAP protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of CTNNB1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein]

NCBI chr 1:228,381,521...228,385,202
Ensembl chr 1:228,381,521...228,385,202

G

DNA methyltransferase 1

decreases expression

Berberine results in decreased expression of DNMT1 mRNA

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

DNA methyltransferase 3 beta

decreases expression

Berberine results in decreased expression of DNMT3B mRNA

NCBI chr 3:142,130,588...142,169,128
Ensembl chr 3:142,130,592...142,169,124

G

DAZ interacting zinc finger protein 3

increases expression

Berberine results in increased expression of DZIP3 mRNA

NCBI chr11:51,823,235...51,893,353
Ensembl chr11:51,823,231...51,893,353

G

epidermal growth factor

multiple interactions

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]

NCBI chr 2:218,219,408...218,302,359
Ensembl chr 2:218,219,415...218,302,064

G

epidermal growth factor receptor

decreases expression

Berberine results in decreased expression of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

eukaryotic translation initiation factor 4E binding protein 1

multiple interactions

Berberine results in decreased phosphorylation of and results in increased expression of EIF4EBP1 protein

NCBI chr16:64,792,595...64,805,984
Ensembl chr16:64,790,226...64,805,984

G

E1A binding protein p300

increases expression

Berberine results in increased expression of EP300 mRNA

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

erb-b2 receptor tyrosine kinase 2

multiple interactions

benzyloxycarbonylleucyl-leucyl-leucine aldehyde inhibits the reaction [Berberine results in decreased expression of ERBB2 protein]; Berberine results in decreased expression of and results in increased ubiquitination of ERBB2 protein

NCBI chr10:83,411,197...83,435,078
Ensembl chr10:83,411,313...83,435,078

G

estrogen receptor 1

multiple interactions

Berberine inhibits the reaction [Estradiol results in increased activity of ESR1 protein]

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

estrogen related receptor, alpha

multiple interactions

Berberine inhibits the reaction [XCT790 results in decreased activity of ESRRA protein]

NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268

G

fatty acid binding protein 4

decreases expression
multiple interactions
increases expression

Berberine results in decreased expression of FABP4 mRNA
15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of FABP4 mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of FABP4 mRNA]

PMID:26478571 PMID:29408570

NCBI chr 2:91,580,879...91,585,567
Ensembl chr 2:91,580,885...91,585,578

G

Fas cell surface death receptor

multiple interactions
increases expression

[Clozapine co-treated with Berberine] results in decreased expression of FAS mRNA; Berberine inhibits the reaction [Risperidone results in increased expression of FAS mRNA]
Berberine results in increased expression of FAS mRNA; Berberine results in increased expression of FAS protein

PMID:20564506 PMID:20656010

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

increases expression

Berberine results in increased expression of FASLG mRNA; Berberine results in increased expression of FASLG protein

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fibronectin 1

multiple interactions

Berberine inhibits the reaction [Thioacetamide results in increased expression of FN1 mRNA]
Berberine inhibits the reaction [Particulate Matter results in increased expression of FN1 mRNA]

PMID:30138605 PMID:37839514

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

forkhead box O1

multiple interactions

[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO1 protein; Berberine results in increased expression of and results in increased acetylation of FOXO1 protein

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

forkhead box O3

multiple interactions

[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of FOXO3 protein; Berberine results in increased expression of and results in increased acetylation of FOXO3 protein

NCBI chr20:45,669,708...45,764,606
Ensembl chr20:45,672,995...45,764,561

G

FUN14 domain containing 1

increases expression
multiple interactions

Berberine results in increased expression of FUNDC1 protein
[Cisplatin co-treated with Berberine] results in increased expression of FUNDC1 protein; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]

NCBI chr X:5,083,635...5,100,293
Ensembl chr X:5,083,617...5,100,284

G

GATA binding protein 2

increases expression

Berberine results in increased expression of GATA2 mRNA

NCBI chr 4:120,654,205...120,667,763
Ensembl chr 4:120,658,986...120,667,761

G

GATA binding protein 3

increases expression

Berberine results in increased expression of GATA3 mRNA

NCBI chr17:68,643,760...68,666,000
Ensembl chr17:68,643,873...68,665,391

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions

Berberine inhibits the reaction [Bortezomib results in increased expression of GCLC mRNA]

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

multiple interactions

Berberine inhibits the reaction [Bortezomib results in increased expression of GCLM mRNA]

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

growth differentiation factor 5

decreases expression

Berberine results in decreased expression of GDF5 mRNA

NCBI chr 3:144,454,316...144,458,508
Ensembl chr 3:144,454,338...144,458,612

G

glial fibrillary acidic protein

multiple interactions

Berberine inhibits the reaction [Bortezomib results in increased expression of GFAP mRNA]

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

glutamic--pyruvic transaminase

multiple interactions

Berberine inhibits the reaction [Ethanol results in increased activity of GPT protein]
Berberine inhibits the reaction [Mercuric Chloride results in increased activity of GPT protein]; Berberine inhibits the reaction [Thioacetamide results in increased activity of GPT protein]

PMID:24751971 PMID:25455889 PMID:30138605

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 1

multiple interactions

Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of GPX1 mRNA]

PMID:24751971 PMID:33460233

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

glycogen synthase kinase 3 beta

multiple interactions
increases phosphorylation

Berberine inhibits the reaction [Dexamethasone results in decreased expression of GSK3B mRNA]
Berberine results in increased phosphorylation of GSK3B protein
Berberine inhibits the reaction [Glucose results in decreased phosphorylation of GSK3B protein]

PMID:20462044 PMID:23954465

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G

glutathione-disulfide reductase

multiple interactions

Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of GSR protein]; Berberine inhibits the reaction [Mercuric Chloride results in decreased activity of GSR protein]

PMID:24751971 PMID:25600690 PMID:33460233 PMID:35439518

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

H2A clustered histone 12

decreases expression

Berberine results in decreased expression of H2AC12 mRNA

NCBI chr17:42,486,415...42,486,880
Ensembl chr17:42,486,415...42,486,941

G

H2A clustered histone 18

decreases expression

Berberine results in decreased expression of H2AC18 mRNA

NCBI chr 2:183,808,398...183,808,992

G

H2A clustered histone 25

decreases expression

Berberine results in decreased expression of H2AC25 mRNA

NCBI chr10:43,733,702...43,735,254
Ensembl chr10:43,733,668...43,744,874

G

H2A clustered histone 4

decreases expression

Berberine results in decreased expression of H2AC4 mRNA

NCBI chr17:42,799,884...42,800,387
Ensembl chr17:42,799,652...42,800,381

G

H2A.X variant histone

increases expression
decreases expression
multiple interactions

Berberine results in increased expression of H2AX protein modified form
Berberine results in decreased expression of H2AX mRNA; Berberine results in decreased expression of H2AX protein
TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form]

PMID:23363784 PMID:23747414 PMID:27311644

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239

G

H2B clustered histone 12

decreases expression

Berberine results in decreased expression of H2BC12 mRNA

NCBI chr17:42,485,699...42,486,162

G

H2B clustered histone 6

decreases expression

Berberine results in decreased expression of H2BC6 mRNA

NCBI chr17:41,520,775...41,521,238

G

H2B clustered histone 8

decreases expression

Berberine results in decreased expression of H2BC8 mRNA

NCBI chr17:42,708,658...42,709,408

G

H2B clustered histone 9

decreases expression

Berberine results in decreased expression of H2BC9 mRNA

NCBI chr17:42,470,593...42,478,590

G

H3 clustered histone 1

decreases expression

Berberine results in decreased expression of H3C1 mRNA

NCBI chr17:41,368,379...41,368,902
Ensembl chr17:41,368,386...41,368,856
Ensembl chr17:41,368,386...41,368,856
Ensembl chr17:41,368,386...41,368,856
Ensembl chr17:41,368,386...41,368,856

G

H3.3 histone A

decreases expression

Berberine results in decreased expression of H3-3A mRNA

NCBI chr13:92,533,289...92,544,902
Ensembl chr13:92,533,298...92,544,908

G

H3.4 histone, cluster member

decreases expression

Berberine results in decreased expression of H3-4 mRNA

NCBI chr10:43,740,702...43,741,262

G

H4 clustered histone 14

decreases expression

Berberine results in decreased expression of H4C2 mRNA

NCBI chr 2:183,831,601...183,831,996
Ensembl chr 2:183,825,994...183,832,048

G

histone acetyltransferase 1

increases expression

Berberine results in increased expression of HAT1 mRNA

NCBI chr 3:56,217,344...56,265,021
Ensembl chr 3:56,217,342...56,275,517

G

histone deacetylase 2

decreases expression

Berberine results in decreased expression of HDAC2 mRNA

NCBI chr20:40,548,244...40,571,609
Ensembl chr20:40,548,250...40,571,609

G

histone deacetylase 5

increases expression

Berberine results in increased expression of HDAC5 mRNA

NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235

G

histone deacetylase 8

decreases expression

Berberine results in decreased expression of HDAC8 mRNA

NCBI chr X:67,385,288...67,593,014
Ensembl chr X:67,385,289...67,592,923

G

histone deacetylase 9

decreases expression
increases expression

Berberine results in decreased expression of HDAC9 mRNA
Berberine results in increased expression of HDAC9 mRNA

NCBI chr 6:50,762,074...51,624,311
Ensembl chr 6:50,763,590...51,625,333

G

hepatocyte growth factor

increases expression
multiple interactions

Berberine results in increased expression of HGF mRNA; Berberine results in increased expression of HGF protein
Berberine inhibits the reaction [Bleomycin results in decreased expression of HGF mRNA]
15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF mRNA]; 15-deoxyprostaglandin J2 promotes the reaction [Berberine results in increased expression of HGF protein]; 2-chloro-5-nitrobenzanilide inhibits the reaction [Berberine results in increased expression of HGF protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF mRNA]; Berberine promotes the reaction [15-deoxyprostaglandin J2 results in increased expression of HGF protein]; Dactinomycin inhibits the reaction [Berberine results in increased expression of HGF protein]; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein]

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

histone cluster 1 H2A family member F

decreases expression

Berberine results in decreased expression of H2AC8 mRNA

NCBI chr17:41,379,404...41,379,796
Ensembl chr17:41,379,404...41,379,796

G

histone cluster 1 H2A family member H

decreases expression

Berberine results in decreased expression of H2AC11 mRNA

NCBI chr17:41,384,521...41,385,018

G

histone cluster 1 H2A family like 1

decreases expression

Berberine results in decreased expression of H2AC6 mRNA

NCBI chr17:42,707,954...42,708,420

G

histone cluster 1 H2B family member D

decreases expression

Berberine results in decreased expression of H2BC5 mRNA

NCBI chr17:42,792,887...42,793,268

G

histone cluster 1 H2B family member Q

decreases expression

Berberine results in decreased expression of H2BC7 mRNA

NCBI chr17:41,432,100...41,441,487
Ensembl chr17:41,429,164...41,442,153

G

histone cluster 1 H4 family member B

decreases expression

Berberine results in decreased expression of H4C9 mRNA

NCBI chr17:42,480,467...42,484,912
Ensembl chr17:42,480,313...42,485,370

G

histone cluster 2 H2B family member E

decreases expression

Berberine results in decreased expression of H2BC11 mRNA

NCBI chr 2:183,780,583...183,783,030

G

high mobility group box 1

multiple interactions

Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of HMGB1 protein]

NCBI chr12:5,972,950...5,979,658
Ensembl chr12:5,901,586...5,978,565
Ensembl chr16:5,901,586...5,978,565

G

heme oxygenase 1

increases expression
multiple interactions

Berberine results in increased expression of HMOX1 protein
Berberine results in increased expression of HMOX1 mRNA; Berberine results in increased expression of HMOX1 protein
Berberine inhibits the reaction [Particulate Matter results in decreased expression of HMOX1 protein]
Berberine inhibits the reaction [Bortezomib results in increased expression of HMOX1 mRNA]
Berberine promotes the reaction [Glucose results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein]

PMID:23954465 PMID:35121005 PMID:37511356 PMID:37839514

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hepatocyte nuclear factor 4, alpha

multiple interactions

Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A mRNA]; Berberine inhibits the reaction [Fructose results in decreased expression of HNF4A protein]
Berberine inhibits the reaction [Ethanol results in decreased expression of HNF4 protein]

PMID:18563319 PMID:25455889

NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320

G

isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha

decreases expression

Berberine results in decreased expression of IDH3A mRNA

NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084

G

interferon gamma

multiple interactions

Berberine inhibits the reaction [Thioacetamide results in increased expression of IFNG mRNA]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor 1 receptor

multiple interactions
increases expression

Berberine inhibits the reaction [Glucose results in decreased expression of IGF1R protein]
Berberine results in increased expression of IGF1R protein

NCBI chr 1:121,549,831...121,838,548
Ensembl chr 1:121,550,743...121,831,777

G

insulin-like growth factor 2 mRNA binding protein 3

multiple interactions
decreases expression

Berberine inhibits the reaction [[Dextran Sulfate co-treated with azomethane] results in increased expression of IGF2BP3 protein]
[Chloroquine co-treated with Berberine] results in decreased expression of IGF2BP3 protein; Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein]; Cycloheximide promotes the reaction [Berberine results in decreased expression of IGF2BP3 protein]

NCBI chr 4:78,060,494...78,195,007
Ensembl chr 4:78,060,494...78,194,865

G

interleukin 10

multiple interactions
increases expression

Berberine affects the reaction [Lipopolysaccharides affects the expression of IL10 mRNA]
[Berberine co-treated with Thioacetamide] results in increased expression of IL10 mRNA
Berberine results in increased expression of IL10 mRNA

PMID:21867779 PMID:30138605

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions

Berberine inhibits the reaction [IL1B protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [IL1B protein results in increased secretion of CXCL8 protein]
Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL1B protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Particulate Matter results in increased expression of IL1B protein]
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL1B protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL1B mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL1B mRNA]

PMID:16391493 PMID:29170048 PMID:30138605 PMID:35121005 PMID:35691465 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

increases expression

Berberine results in increased expression of IL2 mRNA

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 23 subunit alpha

multiple interactions

Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein]

NCBI chr 7:721,809...723,923
Ensembl chr 7:721,809...723,923

G

interleukin 4

multiple interactions
increases expression

Berberine inhibits the reaction [Lipopolysaccharides results in decreased expression of IL4 mRNA]
Berberine results in increased expression of IL4 mRNA

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 6

multiple interactions

Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of IL6 protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Thioacetamide results in increased expression of IL6 protein]
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of IL6 protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [Particulate Matter results in increased expression of IL6 protein]
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]; Berberine inhibits the reaction [Mustard Gas results in increased secretion of IL6 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]

PMID:28916288 PMID:29170048 PMID:30138605 PMID:30240693 PMID:34427876 More...

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 2

multiple interactions

[Berberine co-treated with Streptozocin] results in increased secretion of INS protein

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

integrin subunit alpha 1

increases expression

Berberine results in increased expression of ITGA1 mRNA

NCBI chr 2:46,646,125...46,812,237
Ensembl chr 2:46,653,193...46,812,238

G

integrin subunit beta 4

increases expression

berberine increases expression of ITGB4 protein in colon epithelial cells

RGD

NCBI chr10:101,206,657...101,243,012
Ensembl chr10:101,206,665...101,243,012

G

Jun proto-oncogene, AP-1 transcription factor subunit

affects localization
multiple interactions

Berberine affects the localization of JUN protein
arsenic trioxide promotes the reaction [Berberine affects the localization of JUN protein]

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

potassium voltage-gated channel subfamily H member 2

decreases activity
multiple interactions

Berberine results in decreased activity of KCNH2 protein
Berberine promotes the reaction [Atorvastatin results in decreased activity of KCNH2 protein]; Berberine promotes the reaction [Simvastatin results in decreased activity of KCNH2 protein]

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

lysine demethylase 1A

increases expression

Berberine results in increased expression of KDM1A mRNA

NCBI chr 5:148,782,976...148,838,319
Ensembl chr 5:148,782,976...148,838,319

G

lysine demethylase 4A

increases expression

Berberine results in increased expression of KDM4A mRNA

NCBI chr 5:131,672,754...131,719,534
Ensembl chr 5:131,672,754...131,719,501

G

lysine demethylase 5B

increases expression

Berberine results in increased expression of KDM5B mRNA

NCBI chr13:46,001,589...46,073,868
Ensembl chr13:46,002,542...46,073,872

G

lysine demethylase 6A

increases expression

Berberine results in increased expression of KDM6A mRNA

NCBI chr X:4,337,466...4,477,100
Ensembl chr X:4,337,750...4,477,062

G

lysine demethylase 6B

increases expression

Berberine results in increased expression of KDM6B mRNA

NCBI chr10:54,120,716...54,142,212
Ensembl chr10:54,121,848...54,130,794

G

lysine methyltransferase 5A

increases expression

Berberine results in increased expression of KMT5A mRNA

NCBI chr12:32,139,353...32,167,777
Ensembl chr12:32,139,178...32,162,711

G

karyopherin subunit alpha 4

multiple interactions

Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]

NCBI chr 2:153,319,380...153,381,085
Ensembl chr 2:153,324,273...153,381,081

G

low density lipoprotein receptor

multiple interactions
increases expression

Berberine inhibits the reaction [Clozapine results in increased expression of LDLR mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of LDLR mRNA]
Berberine results in increased expression of LDLR mRNA
Berberine promotes the reaction [Simvastatin results in increased expression of LDLR mRNA]; Simvastatin promotes the reaction [Berberine results in increased expression of LDLR mRNA]

PMID:18640378 PMID:20564506

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

microtubule-associated protein 1 light chain 3 beta

multiple interactions
increases localization

[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein; Berberine results in increased expression of and results in increased lipidation of MAP1LC3B protein; BNIP3L protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]; FUNDC1 protein affects the reaction [[Berberine co-treated with Cisplatin] results in increased lipidation of MAP1LC3B protein]
Berberine results in increased localization of MAP1LC3B protein
Berberine inhibits the reaction [Chlorpyrifos results in decreased expression of MAP1LC3B mRNA]

PMID:35439518 PMID:36070022

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690

G

mitogen-activated protein kinase kinase kinase 5

multiple interactions

Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein]

NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:14,685,492...14,904,800

G

mitogen activated protein kinase 1

decreases phosphorylation

Berberine results in decreased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

decreases phosphorylation
multiple interactions

Berberine results in decreased phosphorylation of MAPK3 protein
Berberine inhibits the reaction [Dexamethasone results in decreased expression of MAPK3 mRNA]

PMID:18294404 PMID:20462044

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

mitogen-activated protein kinase 8

multiple interactions

[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

microtubule-associated protein tau

multiple interactions

Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of MAPT mRNA]

NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129

G

minichromosome maintenance complex component 2

multiple interactions

Berberine inhibits the reaction [Dexamethasone results in increased expression of MCM2 mRNA]

NCBI chr 4:121,346,434...121,360,962
Ensembl chr 4:121,346,434...121,360,847

G

microRNA 142

multiple interactions

Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased expression of MIR142 mRNA]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of IL6 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of KPNA4 protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]

NCBI chr10:72,557,864...72,557,950
Ensembl chr10:72,557,857...72,557,967

G

microRNA 19a

decreases expression

Berberine results in decreased expression of MIR19A mRNA

NCBI chr15:92,180,912...92,180,993
Ensembl chr15:92,180,912...92,180,993

G

microRNA 21

decreases expression

berberine decreases expression of MIR21 RNA in colon epithelial cell

RGD

NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348

G

microRNA 92a-1

decreases expression

Berberine results in decreased expression of MIR92A1 mRNA

NCBI chr15:92,181,336...92,181,413
Ensembl chr15:92,181,336...92,181,413

G

matrix metallopeptidase 13

increases expression

Berberine results in increased expression of MMP13 mRNA

NCBI chr 8:4,497,960...4,508,239
Ensembl chr 8:4,497,960...4,508,239

G

matrix metallopeptidase 14

multiple interactions
decreases expression

arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP14 protein]

NCBI chr15:27,887,795...27,897,020
Ensembl chr15:27,887,727...27,899,864

G

matrix metallopeptidase 2

multiple interactions
decreases activity
decreases expression

2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]]; Arsenic Trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; Berberine promotes the reaction [Arsenic Trioxide results in decreased activity of MMP2 protein]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP2 protein]
Berberine results in decreased expression of MMP2 protein
arsenic trioxide promotes the reaction [Berberine results in decreased activity of MMP2 protein]; arsenic trioxide promotes the reaction [Berberine results in decreased expression of MMP2 protein]; Berberine promotes the reaction [arsenic trioxide results in decreased activity of MMP2 protein]

PMID:18294404 PMID:33325633

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

decreases activity
multiple interactions

Berberine results in decreased activity of MMP9 protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]]; EGF protein inhibits the reaction [Berberine results in decreased activity of MMP9 protein]

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions

Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mitochondrially encoded cytochrome c oxidase I

multiple interactions

Berberine inhibits the reaction [acetamiprid results in decreased expression of COX1 mRNA]

NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
NCBI chr MT:5,323...6,867
Ensembl chr MT:5,323...6,867

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1

multiple interactions

Berberine inhibits the reaction [acetamiprid results in decreased expression of ND1 mRNA]

NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
NCBI chr MT:2,740...3,694
Ensembl chr MT:2,740...3,694

G

mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 2

multiple interactions

Berberine inhibits the reaction [acetamiprid results in decreased expression of ND2 mRNA]

NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
NCBI chr MT:3,904...4,942
Ensembl chr MT:3,904...4,942

G

mechanistic target of rapamycin kinase

multiple interactions

Berberine inhibits the reaction [Chlorpyrifos results in increased expression of MTOR mRNA]; Berberine inhibits the reaction [Chlorpyrifos results in increased expression of MTOR protein]

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

microsomal triglyceride transfer protein

multiple interactions

Berberine inhibits the reaction [Ethanol results in decreased expression of MTTP protein]

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

MYC proto-oncogene, bHLH transcription factor

multiple interactions
affects localization

arsenic trioxide promotes the reaction [Berberine affects the localization of MYC protein]

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

nicotinamide phosphoribosyltransferase

multiple interactions
decreases expression

[Berberine co-treated with Niacinamide] results in decreased expression of NAMPT protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of NAMPT protein]

NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100

G

neutrophil cytosolic factor 1

multiple interactions

Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF1 protein]

NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646

G

neutrophil cytosolic factor 2

multiple interactions

Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to NCF2 protein]

NCBI chr13:64,955,622...64,986,144
Ensembl chr13:64,955,503...64,986,277

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions
increases activity

Berberine results in increased expression of NFE2L2 protein
Berberine inhibits the reaction [Particulate Matter results in decreased expression of NFE2L2 protein]
Berberine results in increased activity of NFE2L2 protein
Berberine inhibits the reaction [Bortezomib results in increased expression of NFE2L2 mRNA]; Berberine promotes the reaction [Bleomycin results in increased expression of NFE2L2 protein]
NFE2L2 mutant form inhibits the reaction [Berberine inhibits the reaction [Glucose results in increased abundance of Reactive Oxygen Species]]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of HMOX1 protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein]

PMID:23523906 PMID:23954465 PMID:30818834 PMID:35121005 PMID:37839514

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

multiple interactions

Berberine inhibits the reaction [Bortezomib results in increased expression of NFKB1 mRNA]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NFKB inhibitor alpha

multiple interactions

Berberine inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of NFKBIA protein]
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of NFKBIA protein]]

PMID:21963898 PMID:34427876

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nerve growth factor

multiple interactions

Berberine inhibits the reaction [Glucose results in decreased expression of NGF protein]; NFE2L2 mutant form inhibits the reaction [Berberine results in increased expression of NGF protein]

NCBI chr 2:189,901,058...189,954,452
Ensembl chr 2:189,901,058...189,954,452

G

NLR family, pyrin domain containing 3

multiple interactions

Berberine inhibits the reaction [Bortezomib results in increased expression of NLRP3 mRNA]
Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 mRNA]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of NLRP3 protein]

PMID:35121005 PMID:38705399

NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811

G

nitric oxide synthase 2

multiple interactions

Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of NOS2 protein]
Berberine inhibits the reaction [Bleomycin results in increased expression of NOS2 protein]

PMID:21095217 PMID:23523906

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

NAD(P)H quinone dehydrogenase 1

multiple interactions

Berberine reverses reaction [Carbon tetrachloride decreases Nqo1 mRNA in liver]
Berberine inhibits the reaction [Bortezomib results in increased expression of NQO1 mRNA]

CTD
RGD

PMID:35121005 PMID:31432116

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 1, group H, member 3

increases localization

Berberine increases localization of NR1H3 protein in macrophage nucleus

RGD

NCBI chr 3:77,158,808...77,168,907
Ensembl chr 3:77,158,808...77,168,722

G

nuclear receptor subfamily 1, group I, member 2

increases activity
multiple interactions

Berberine results in increased activity of NR1I2 protein
[Berberine results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

G

nuclear receptor subfamily 1, group I, member 3

increases activity

Berberine results in increased activity of NR1I3 protein

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nuclear receptor binding SET domain protein 2

decreases expression

Berberine results in decreased expression of NSD2 mRNA

NCBI chr14:76,833,179...76,911,304
Ensembl chr14:76,835,637...76,913,641

G

ornithine decarboxylase 1

multiple interactions
decreases expression

arsenic trioxide promotes the reaction [Berberine results in decreased expression of ODC1 protein]

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

osteomodulin

increases expression

Berberine results in increased expression of OMD mRNA

NCBI chr17:15,060,217...15,068,441
Ensembl chr17:15,060,217...15,068,441

G

purinergic receptor P2X 7

multiple interactions

Berberine affects the reaction [3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate results in increased activity of P2RX7 protein]

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions

Berberine results in increased cleavage of PARP1 protein
[Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein; [Berberine co-treated with Niacinamide] results in increased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [[Berberine co-treated with Cisplatin] results in increased cleavage of PARP1 protein]

PMID:16505103 PMID:26712469 PMID:36070022

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

programmed cell death 4

increases expression

Berberine increases expression of PDCD4 protein in colon epithelial cells

RGD

NCBI chr 1:252,921,342...252,944,278
Ensembl chr 1:252,921,392...252,944,275

G

pyruvate dehydrogenase kinase 4

increases expression

Berberine results in increased expression of PDK4 mRNA

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

peroxisome proliferator activated receptor alpha

multiple interactions

Berberine inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA]
Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in increased expression of PPARA protein]

PMID:18338635 PMID:25455889

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor delta

increases activity
multiple interactions
increases expression

Berberine results in increased activity of PPARD protein
Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in increased expression of PPARD protein]
Berberine results in increased expression of PPARD mRNA; Berberine results in increased expression of PPARD protein

PMID:18338635 PMID:37511356

NCBI chr20:6,298,785...6,363,970
Ensembl chr20:6,298,785...6,363,968

G

peroxisome proliferator-activated receptor gamma

multiple interactions
decreases expression
increases response to substance
increases expression

Berberine inhibits the reaction [Clozapine results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of PPARG protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of PPARG protein]
Berberine inhibits the reaction [[Streptozocin co-treated with Dietary Fats co-treated with Dietary Carbohydrates] results in decreased expression of PPARG protein]
Berberine results in decreased expression of PPARG mRNA; Berberine results in decreased expression of PPARG protein
15-deoxyprostaglandin J2 promotes the reaction [Berberine affects the localization of and results in increased activity of PPARG protein]; Berberine inhibits the reaction [Bleomycin binds to PPARG protein]; Berberine promotes the reaction [15-deoxyprostaglandin J2 affects the localization of and results in increased activity of PPARG protein]; Berberine results in increased activity of and affects the localization of PPARG protein; PPARG mRNA promotes the reaction [Berberine results in increased expression of HGF protein]
PPARG mRNA results in increased susceptibility to Berberine
Berberine results in increased expression of PPARG mRNA

PMID:18338635 PMID:20564506 PMID:26478571 PMID:29408570 PMID:37511356 More...

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

multiple interactions

Berberine inhibits the reaction [Ethanol results in decreased expression of PPARGC1A mRNA]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

proteoglycan 4

decreases expression

Berberine results in decreased expression of PRG4 mRNA

NCBI chr13:62,487,257...62,504,657
Ensembl chr13:62,487,257...62,504,119

G

protein kinase AMP-activated catalytic subunit alpha 1

increases phosphorylation

Berberine results in increased phosphorylation of PRKAA1 protein

NCBI chr 2:54,240,298...54,275,978
Ensembl chr 2:54,240,137...54,275,978

G

protein kinase C, alpha

multiple interactions

arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCA protein]; Berberine results in decreased activity of and affects the localization of PRKCA protein

NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012

G

protein kinase C, epsilon

multiple interactions
decreases activity

arsenic trioxide promotes the reaction [Berberine results in decreased activity of PRKCE protein]; Berberine results in decreased activity of and affects the localization of PRKCE protein

NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719

G

protein arginine methyltransferase 1

decreases expression

Berberine results in decreased expression of PRMT1 mRNA

NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345

G

protein arginine methyltransferase 2

increases expression

Berberine results in increased expression of PRMT2 mRNA

NCBI chr20:12,394,748...12,420,643
Ensembl chr20:12,394,798...12,420,643

G

protein arginine methyltransferase 5

increases expression

Berberine results in increased expression of PRMT5 mRNA

NCBI chr15:27,968,893...27,978,291
Ensembl chr15:27,968,910...27,978,296

G

protein arginine methyltransferase 6

increases expression

Berberine results in increased expression of PRMT6 mRNA

NCBI chr 2:197,927,750...197,932,760
Ensembl chr 2:197,927,220...197,933,648

G

protein arginine methyltransferase 7

increases expression

Berberine results in increased expression of PRMT7 mRNA

NCBI chr19:34,110,724...34,161,531
Ensembl chr19:34,110,747...34,162,577

G

protein arginine methyltransferase 8

increases expression

Berberine results in increased expression of PRMT8 mRNA

NCBI chr 4:160,535,813...160,618,193
Ensembl chr 4:160,535,813...160,617,930

G

phosphatase and tensin homolog

multiple interactions
increases expression

((3Z)-N-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-N-methyl-2-oxo-2,3-dihydro-1H-indole-5-sulfonamide) inhibits the reaction [Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN mRNA]; Berberine inhibits the reaction [Bleomycin results in decreased expression of PTEN protein]
Berberine results in increased expression of PTEN protein

NCBI chr 1:230,630,443...230,697,070
Ensembl chr 1:230,630,338...230,696,838

G

prostaglandin-endoperoxide synthase 2

multiple interactions

Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

PYD and CARD domain containing

multiple interactions

Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of PYCARD mRNA]

NCBI chr 1:182,601,657...182,603,013
Ensembl chr 1:182,601,174...182,602,955

G

Rac family small GTPase 2

multiple interactions

Berberine promotes the reaction [CYBB protein binds to NCF1 protein binds to NCF2 protein binds to RAC2 protein]; Berberine promotes the reaction [CYBB protein binds to RAC2 protein]; Berberine results in increased expression of and results in increased activity of RAC2 protein

NCBI chr 7:110,101,344...110,128,718
Ensembl chr 7:110,116,260...110,128,720

G

retinol binding protein 4

multiple interactions

Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in increased secretion of RBP4 protein]

NCBI chr 1:235,893,917...235,901,315
Ensembl chr 1:235,893,917...235,901,399

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Berberine inhibits the reaction [Bleomycin affects the localization of and results in increased expression of RELA protein]
Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of RELA protein]]

PMID:23523906 PMID:34427876

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

relaxin 1

affects binding
increases expression
multiple interactions

Berberine binds to RLN1 promoter
Berberine results in increased expression of RLN1 mRNA
[Berberine binds to RLN1 promoter] which results in increased expression of RLN1 mRNA

NCBI chr 1:227,079,960...227,082,960
Ensembl chr 1:227,079,966...227,082,882

G

ribosomal protein S6

decreases phosphorylation

Berberine results in decreased phosphorylation of RPS6 protein

NCBI chr 5:101,371,716...101,374,576
Ensembl chr 5:101,371,136...101,374,602
Ensembl chr 5:101,371,136...101,374,602

G

RUNX family transcription factor 2

multiple interactions
increases expression

CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]; DKK1 protein inhibits the reaction [Berberine results in increased expression of RUNX2 mRNA]

NCBI chr 9:16,167,504...16,492,826
Ensembl chr 9:16,167,482...16,492,167

G

SET domain containing 1B, histone lysine methyltransferase

increases expression

Berberine results in increased expression of SETD1B mRNA

NCBI chr12:33,395,963...33,421,671
Ensembl chr12:33,396,120...33,426,934

G

SET domain containing 2, histone lysine methyltransferase

increases expression

Berberine results in increased expression of SETD2 mRNA

NCBI chr 8:110,511,808...110,597,475
Ensembl chr 8:110,511,772...110,597,489

G

SET domain containing 3, actin N3(tau)-histidine methyltransferase

increases expression

Berberine results in increased expression of SETD3 mRNA

NCBI chr 6:127,023,058...127,090,020
Ensembl chr 6:127,023,058...127,090,008

G

SET domain containing 5

increases expression

Berberine results in increased expression of SETD5 mRNA

NCBI chr 4:146,217,172...146,294,896
Ensembl chr 4:146,217,180...146,294,894

G

SET domain containing 6, protein lysine methyltransferase

increases expression

Berberine results in increased expression of SETD6 mRNA

NCBI chr19:9,343,309...9,350,477
Ensembl chr19:9,347,458...9,350,453

G

SET domain containing 7, histone lysine methyltransferase

increases expression

Berberine results in increased expression of SETD7 mRNA

NCBI chr 2:135,562,683...135,605,468
Ensembl chr 2:135,562,683...135,605,468

G

SET domain bifurcated histone lysine methyltransferase 1

increases expression

Berberine results in increased expression of SETDB1 mRNA

NCBI chr 2:182,898,738...182,930,283
Ensembl chr 2:182,898,738...182,930,506

G

SET domain bifurcated histone lysine methyltransferase 2

increases expression

Berberine results in increased expression of SETDB2 mRNA

NCBI chr15:33,553,657...33,606,586
Ensembl chr15:33,453,952...33,606,470

G

sucrase-isomaltase

decreases expression
multiple interactions

Berberine results in decreased expression of SI mRNA
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Berberine results in decreased expression of SI mRNA]

NCBI chr 2:157,505,893...157,586,228
Ensembl chr 2:157,506,342...157,585,260

G

sirtuin 1

decreases expression
multiple interactions

Berberine results in decreased expression of SIRT1 mRNA; Berberine results in decreased expression of SIRT1 protein
Berberine inhibits the reaction [Bortezomib results in decreased expression of SIRT1 protein]
[Berberine co-treated with Niacinamide] results in decreased expression of SIRT1 protein; SRT1720 inhibits the reaction [Berberine results in decreased expression of SIRT1 protein]

PMID:26712469 PMID:35121005

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

sirtuin 2

multiple interactions

[Berberine co-treated with Niacinamide] results in decreased expression of SIRT2 protein

NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975

G

sirtuin 3

multiple interactions
increases expression
decreases expression

[Berberine co-treated with Niacinamide] results in decreased expression of SIRT3 protein
Berberine results in increased expression of SIRT3 mRNA
Berberine results in decreased expression of SIRT3 mRNA; Berberine results in decreased expression of SIRT3 protein

PMID:26712469 PMID:27311644

NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808

G

solute carrier family 27 member 5

decreases expression

Berberine results in decreased expression of SLC27A5 mRNA

NCBI chr 1:73,616,556...73,627,149
Ensembl chr 1:73,616,564...73,627,172

G

solute carrier family 2 member 4

multiple interactions

Berberine inhibits the reaction [[Dietary Fats co-treated with Streptozocin] results in decreased expression of SLC2A4 protein]

NCBI chr10:54,666,015...54,671,581
Ensembl chr10:54,666,015...54,671,565

G

solute carrier family 6 member 19

multiple interactions

Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 mRNA]; Berberine affects the reaction [Lipopolysaccharides affects the expression of SLC6A19 protein]

NCBI chr 1:29,586,191...29,604,964
Ensembl chr 1:29,586,195...29,604,962

G

SET and MYND domain containing 3

affects expression

Berberine affects the expression of SMYD3 mRNA

NCBI chr13:90,709,263...91,266,209
Ensembl chr13:90,709,270...91,266,253

G

suppressor of cytokine signaling 3

multiple interactions

Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOCS3 mRNA]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOCS3 protein]

NCBI chr10:103,193,909...103,197,322
Ensembl chr10:103,193,537...103,197,787

G

superoxide dismutase 1

multiple interactions

Berberine inhibits the reaction [Carbon Tetrachloride results in decreased activity of SOD1 protein]; Berberine inhibits the reaction [Particulate Matter results in decreased expression of SOD1 protein]; Berberine inhibits the reaction [Streptozocin affects the expression of SOD1 mRNA]
Berberine inhibits the reaction [Chlorpyrifos results in decreased activity of SOD1 protein]

PMID:21095217 PMID:22775417 PMID:35439518 PMID:37839514

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions

Berberine inhibits the reaction [Streptozocin affects the expression of SOD2 mRNA]
Berberine inhibits the reaction [acetamiprid results in decreased expression of SOD2 mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in decreased expression of SOD2 mRNA]

PMID:22775417 PMID:24751971 PMID:33460233 PMID:37350525

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

SRY-box transcription factor 9

decreases expression

Berberine results in decreased expression of SOX9 mRNA

NCBI chr10:97,806,485...97,811,994
Ensembl chr10:97,806,485...97,811,994

G

Sp7 transcription factor

increases expression

Berberine results in increased expression of SP7 mRNA

NCBI chr 7:133,484,609...133,494,788
Ensembl chr 7:133,484,609...133,494,847

G

secreted protein acidic and cysteine rich

increases expression

Berberine results in increased expression of SPARC mRNA

NCBI chr10:39,516,394...39,538,252
Ensembl chr10:39,516,406...39,538,396

G

secreted phosphoprotein 1

increases expression
multiple interactions

Berberine results in increased expression of SPP1 mRNA; Berberine results in increased expression of SPP1 protein
CTNNB1 mutant form inhibits the reaction [Berberine results in increased expression of SPP1 protein]; DKK1 protein inhibits the reaction [Berberine results in increased expression of SPP1 protein]

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

sequestosome 1

increases expression
multiple interactions

Berberine results in increased expression of SQSTM1 protein
[Berberine co-treated with Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of SQSTM1 protein

PMID:36070022 PMID:38705399

NCBI chr10:34,525,517...34,536,670
Ensembl chr10:34,525,519...34,536,673

G

sterol regulatory element binding transcription factor 1

multiple interactions
decreases expression

Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Clozapine results in increased expression of SREBF1 protein]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 mRNA]; Berberine inhibits the reaction [Risperidone results in increased expression of SREBF1 protein]
Berberine results in decreased expression of SREBF1 mRNA

PMID:20564506 PMID:26478571

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

signal transducer and activator of transcription 3

multiple interactions

Berberine inhibits the reaction [Bortezomib results in increased expression of STAT3 mRNA]
Berberine inhibits the reaction [Particulate Matter results in increased expression of STAT3 mRNA]

PMID:35121005 PMID:37839514

NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057

G

telomerase reverse transcriptase

decreases activity

Berberine results in decreased activity of TERT protein

NCBI chr 1:29,637,213...29,659,561
Ensembl chr 1:29,637,506...29,659,561

G

transforming growth factor, beta 1

decreases expression
multiple interactions

Berberine results in decreased expression of TGFB1 protein
Berberine inhibits the reaction [Particulate Matter results in increased expression of TGFB1 mRNA]
Berberine inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]; Berberine inhibits the reaction [Thioacetamide results in increased expression of TGFB1 mRNA]

PMID:17973934 PMID:23523906 PMID:30138605 PMID:37839514

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

toll-like receptor 4

multiple interactions

Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TLR4 mRNA]
Berberine inhibits the reaction [Bortezomib results in increased expression of TLR4 protein]

PMID:21963898 PMID:30240693 PMID:35121005

NCBI chr 5:80,145,867...80,159,501
Ensembl chr 5:80,145,826...80,159,628

G

tumor necrosis factor

multiple interactions
increases secretion
increases expression

Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]; Berberine inhibits the reaction [TNF protein results in increased expression of CCL2 mRNA]; Berberine inhibits the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Berberine inhibits the reaction [TNF protein results in increased secretion of CCL2 protein]; Berberine inhibits the reaction [TNF protein results in increased secretion of CXCL8 protein]; KPNA4 protein inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; LINC00943 inhibits the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]; MIR142 affects the reaction [Berberine inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased expression of TNF protein]]
Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Cadmium co-treated with Aluminum co-treated with Fluorides] results in increased expression of TNF protein]; Berberine inhibits the reaction [Bleomycin results in increased expression of TNF protein]; Berberine inhibits the reaction [Bortezomib results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Mercuric Chloride results in increased expression of TNF protein]
Berberine results in increased secretion of TNF protein
Berberine results in increased expression of TNF mRNA
Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in decreased expression of and results in increased phosphorylation of MAP3K5 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL23A mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of IL6 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TLR4 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL23A protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of IL6 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TLR4 protein]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [[Lipopolysaccharides co-treated with Galactosamine] results in increased expression of TNF protein]; Berberine inhibits the reaction [[Water deficiency co-treated with NG-Nitroarginine Methyl Ester co-treated with Indomethacin co-treated with Iohexol] results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Carbon Tetrachloride results in increased expression of TNF protein]; Berberine inhibits the reaction [Dietary Fats results in increased secretion of TNF protein]; Berberine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Berberine inhibits the reaction [Particulate Matter results in increased expression of TNF protein]

PMID:16391493 PMID:20656010 PMID:21095217 PMID:21867779 PMID:23523906 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

DNA topoisomerase I

decreases activity

Berberine results in decreased activity of TOP1 protein

NCBI chr 3:149,293,469...149,376,618
Ensembl chr 3:149,293,403...149,376,623

G

DNA topoisomerase II alpha

multiple interactions
affects response to substance

TOP2A protein affects the reaction [Berberine results in increased expression of H2AX protein modified form]
TOP2A protein affects the susceptibility to Berberine

NCBI chr10:83,945,731...83,976,874
Ensembl chr10:83,945,735...83,976,874

G

tumor protein p53

increases expression
multiple interactions

Berberine results in increased expression of TP53 mRNA; Berberine results in increased expression of TP53 protein
[Berberine co-treated with Niacinamide] results in increased expression of and results in increased acetylation of TP53 protein; Berberine results in increased phosphorylation of and results in increased acetylation of TP53 protein

PMID:20656010 PMID:26712469

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

TNF receptor-associated factor 1

increases expression

Berberine results in increased expression of TRAF1 protein

NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807

G

Tnf receptor-associated factor 2

multiple interactions

Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased expression of TRAF2 mRNA]; Berberine inhibits the reaction [[lipopolysaccharide, Escherichia coli O111 B4 co-treated with TNF protein] results in increased secretion of TRAF2 protein]

NCBI chr 3:8,341,950...8,366,609
Ensembl chr 3:8,341,951...8,366,538

G

tripartite motif-containing 21

multiple interactions

Berberine promotes the reaction [IGF2BP3 protein binds to TRIM21 protein]

NCBI chr 1:156,964,896...156,987,504
Ensembl chr 1:156,964,913...156,987,440

G

thiosulfate sulfurtransferase like domain containing 1

increases expression

Berberine results in increased expression of TSTD1 mRNA

NCBI chr13:83,853,421...83,854,875
Ensembl chr13:83,822,035...83,854,885

G

ubiquitin-conjugating enzyme E2A

decreases expression

Berberine results in decreased expression of UBE2A mRNA

NCBI chr X:116,114,339...116,125,076
Ensembl chr X:116,113,875...116,125,070

G

ubiquitin-conjugating enzyme E2B

decreases expression

Berberine results in decreased expression of UBE2B mRNA

NCBI chr10:36,248,434...36,263,379
Ensembl chr10:36,248,438...36,264,665

G

uncoupling protein 2

multiple interactions
increases expression

Berberine inhibits the reaction [Benzo(a)pyrene results in increased expression of UCP2 mRNA]
Berberine results in increased expression of UCP2 mRNA

PMID:28533128 PMID:37511356

NCBI chr 1:154,839,242...154,845,612
Ensembl chr 1:154,839,209...154,845,611

G

vascular endothelial growth factor A

decreases expression

Berberine results in decreased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

G

vascular endothelial growth factor C

increases expression

Berberine results in increased expression of VEGFC mRNA

NCBI chr16:37,712,251...37,827,845
Ensembl chr16:37,712,262...37,827,848

entacapone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA oxidase 3, pristanoyl

affects binding

entacapone binds to ACOX3 protein

NCBI chr14:75,133,986...75,176,767
Ensembl chr14:75,094,676...75,176,205

G

acyl-CoA synthetase long-chain family member 1

affects binding

entacapone binds to ACSL1 protein

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

ADP-ribosylhydrolase like 1

affects binding

entacapone binds to ADPRHL1 protein

NCBI chr16:76,283,186...76,315,075
Ensembl chr16:76,283,103...76,354,440

G

AU RNA binding methylglutaconyl-CoA hydratase

affects binding

entacapone binds to AUH protein

NCBI chr17:12,329,522...12,424,882
Ensembl chr17:12,329,524...12,424,896

G

clathrin heavy chain

affects binding

entacapone binds to CLTC protein

NCBI chr10:71,517,661...71,574,591
Ensembl chr10:71,517,663...71,573,737

G

catechol-O-methyltransferase

decreases activity
affects binding
multiple interactions

entacapone results in decreased activity of COMT protein
entacapone binds to COMT protein
[entacapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; entacapone inhibits the reaction [COMT protein results in increased methylation of Levodopa]

PMID:12898346 PMID:15566291 PMID:19783845 PMID:20334432 PMID:23206800 More...

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

enoyl-CoA hydratase, short chain 1

affects binding

entacapone binds to ECHS1 protein

NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884

G

epiregulin

increases expression

entacapone results in increased expression of EREG mRNA

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

glycerol-3-phosphate acyltransferase, mitochondrial

decreases expression

entacapone results in decreased expression of GPAM protein

NCBI chr 1:254,106,323...254,170,755
Ensembl chr 1:254,106,331...254,142,639

G

hemoglobin subunit beta

affects binding

entacapone binds to HBB protein

NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012

G

hydroxysteroid (17-beta) dehydrogenase 13

affects binding

entacapone binds to HSD17B13 protein

NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166

G

hydroxysteroid (17-beta) dehydrogenase 4

affects binding

entacapone binds to HSD17B4 protein

NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952

G

interleukin 1 alpha

increases expression

entacapone results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression

entacapone results in increased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

entacapone results in increased expression of MET mRNA

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

pyruvate carboxylase

affects binding

entacapone binds to PC protein

NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380

G

phosphotyrosine interaction domain containing 1

decreases expression

entacapone results in decreased expression of PID1 mRNA

NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044

G

prostaglandin-endoperoxide synthase 2

increases expression

entacapone results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

solute carrier family 7 member 11

decreases expression

entacapone results in decreased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

secretory leukocyte peptidase inhibitor

decreases expression

entacapone results in decreased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

synuclein alpha

multiple interactions

entacapone inhibits the reaction [SNCA protein binds to SNCA protein]

NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262

G

sulfotransferase family 2A member 1

affects binding

entacapone binds to SULT2A1 protein

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

TNF alpha induced protein 6

decreases expression

entacapone results in decreased expression of TNFAIP6 mRNA

NCBI chr 3:36,502,250...36,521,652
Ensembl chr 3:36,502,188...36,521,649

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation

UGT1A1 protein results in increased glucuronidation of entacapone

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases glucuronidation

UGT1A3 protein results in increased glucuronidation of entacapone

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 1 member A9

increases glucuronidation
decreases glucuronidation

UGT1A9 protein results in increased glucuronidation of entacapone
UGT1A9 protein mutant form results in decreased glucuronidation of entacapone

PMID:15044611 PMID:15802387 PMID:16344532

NCBI chr 9:88,696,981...88,808,465
Ensembl chr 9:88,713,184...88,808,465

GSK343

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

dicer 1 ribonuclease III

increases expression

GSK343 results in increased expression of DICER1 mRNA

NCBI chr 6:123,627,529...123,692,278
Ensembl chr 6:123,631,250...123,693,965

G

enhancer of zeste 2 polycomb repressive complex 2 subunit

decreases activity

GSK343 results in decreased activity of EZH2 protein

PMID:23759589 PMID:24900432

NCBI chr 4:76,624,399...76,687,362
Ensembl chr 4:76,624,399...76,687,362

LLY-507

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

CD36 molecule

multiple interactions

[LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

interferon gamma

multiple interactions

[LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of CD36 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MARCO mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MMP9 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MSR1 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of IL6 mRNA; [LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of TNF mRNA

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 6

multiple interactions

[LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

macrophage receptor with collagenous structure

multiple interactions

[LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MARCO mRNA

NCBI chr13:31,616,278...31,648,521
Ensembl chr13:31,616,278...31,648,521

G

matrix metallopeptidase 9

multiple interactions

[LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MMP9 mRNA

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

macrophage scavenger receptor 1

multiple interactions

[LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in decreased expression of MSR1 mRNA

NCBI chr16:52,717,775...52,803,602
Ensembl chr16:52,717,732...52,799,676

G

SET and MYND domain containing 2

multiple interactions

LLY-507 binds to and results in decreased activity of SMYD2 protein

NCBI chr13:101,425,270...101,466,576
Ensembl chr13:101,425,273...101,466,576

G

tumor necrosis factor

multiple interactions

[LLY-507 affects the susceptibility to [Lipopolysaccharides co-treated with IFNG protein]] which results in increased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

N-ethylmaleimide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

decreases activity

Ethylmaleimide results in decreased activity of ABCB1 protein

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 1

affects activity
multiple interactions

Ethylmaleimide affects the activity of ABCC1 protein
Ethylmaleimide inhibits the reaction [ABCC1 protein results in increased export of 2',7'-bis-(carboxypropyl)-5(6)-carboxyfluorescein]

PMID:9096673 PMID:9334814 PMID:16101123

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

acyl-CoA synthetase long-chain family member 4

decreases activity

Ethylmaleimide results in decreased activity of ACSL4 protein

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

albumin

decreases transport

Ethylmaleimide results in decreased transport of ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

apurinic/apyrimidinic endodeoxyribonuclease 1

multiple interactions

Ethylmaleimide inhibits the reaction [APEX1 protein inhibits the reaction [Hydrogen Peroxide results in decreased activity of MAPK1 protein]]

NCBI chr15:24,144,595...24,146,785
Ensembl chr15:24,144,362...24,146,785

G

ATPase copper transporting alpha

multiple interactions
increases glutathionylation

Dithiothreitol inhibits the reaction [Ethylmaleimide results in increased glutathionylation of ATP7A protein]

NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354

G

ATPase phospholipid transporting 8B1

multiple interactions

Ethylmaleimide inhibits the reaction [ATP8B1 protein results in increased transport of Phosphatidylserines]

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:58,018,268...58,157,396

G

carbonyl reductase 2

increases acylation

Ethylmaleimide results in increased acylation of CBR2 protein

NCBI chr10:106,008,535...106,012,838
Ensembl chr10:105,991,589...106,013,001

G

CF transmembrane conductance regulator

multiple interactions

Ethylmaleimide inhibits the reaction [Glutathione results in decreased activity of CFTR protein]

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

choline O-acetyltransferase

decreases activity

Ethylmaleimide results in decreased activity of CHAT protein

NCBI chr16:7,657,362...7,717,093
Ensembl chr16:7,657,362...7,717,093

G

component of inhibitor of nuclear factor kappa B kinase complex

multiple interactions

Ethylmaleimide inhibits the reaction [Lipopolysaccharides results in increased activity of CHUK protein]

NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065

G

dual specificity phosphatase 23

multiple interactions

Ethylmaleimide inhibits the reaction [DUSP23 protein results in decreased phosphorylation of nitrophenylphosphate]

NCBI chr13:85,097,899...85,100,054
Ensembl chr13:85,097,899...85,100,093

G

coagulation factor III, tissue factor

increases expression

Ethylmaleimide results in increased expression of F3 protein

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

glutamate decarboxylase 1

decreases activity

Ethylmaleimide results in decreased activity of GAD1 protein

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

glutamate decarboxylase 2

decreases activity

Ethylmaleimide results in decreased activity of GAD2 protein

NCBI chr17:84,763,630...84,826,155
Ensembl chr17:84,763,628...84,826,155

G

homeo box B13

increases response to substance

HOXB13 protein results in increased susceptibility to Ethylmaleimide

NCBI chr10:81,160,498...81,162,777
Ensembl chr10:81,160,498...81,162,777

G

hydroxysteroid 11-beta dehydrogenase 2

multiple interactions

Ethylmaleimide promotes the reaction [Thiram results in decreased activity of HSD11B2 protein]

NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899

G

interleukin 1 alpha

multiple interactions

Ethylmaleimide inhibits the reaction [IL1A protein results in increased expression of SOD2 mRNA]; Ethylmaleimide inhibits the reaction [IL1A protein results in increased expression of SOD2 protein]

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

lymphotoxin beta receptor

multiple interactions

Ethylmaleimide promotes the reaction [OSM protein binds to LTBR protein]

NCBI chr 4:158,108,884...158,115,339
Ensembl chr 4:158,108,886...158,121,539

G

mitogen activated protein kinase 1

multiple interactions

Ethylmaleimide inhibits the reaction [APEX1 protein inhibits the reaction [Hydrogen Peroxide results in decreased activity of MAPK1 protein]]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

metallothionein 3

increases alkylation

Ethylmaleimide results in increased alkylation of MT3 protein

NCBI chr19:10,848,754...10,850,158
Ensembl chr19:10,848,755...10,850,158

G

oncostatin M

multiple interactions

Ethylmaleimide promotes the reaction [OSM protein binds to LTBR protein]

NCBI chr14:79,103,638...79,108,500
Ensembl chr14:79,104,344...79,108,313

G

phenylalanine hydroxylase

multiple interactions

Ethylmaleimide results in increased activity of [PAH protein binds to PAH protein binds to PAH protein binds to PAH protein]

NCBI chr 7:21,933,179...21,998,134
Ensembl chr 7:21,933,179...21,998,130

G

SUMO specific peptidase 1

multiple interactions

Ethylmaleimide inhibits the reaction [SUMO2 protein binds to SENP1 protein]

NCBI chr 7:129,163,173...129,226,766
Ensembl chr 7:129,165,774...129,221,598

G

SUMO specific peptidase 6

multiple interactions

Ethylmaleimide inhibits the reaction [SUMO2 protein binds to SENP6 protein]

NCBI chr 8:80,988,675...81,071,606
Ensembl chr 8:80,989,052...81,067,170

G

solute carrier family 12 member 5

increases activity
multiple interactions

Ethylmaleimide results in increased activity of SLC12A5 protein
Ethylmaleimide inhibits the reaction [SLC12A5 protein results in increased import of Thallium]

NCBI chr 3:153,696,517...153,735,801
Ensembl chr 3:153,696,517...153,735,765

G

solute carrier family 16 member 1

multiple interactions

Ethylmaleimide inhibits the reaction [SLC16A1 protein results in increased uptake of Lactic Acid]

NCBI chr 2:192,123,755...192,144,617
Ensembl chr 2:192,124,289...192,144,611

G

superoxide dismutase 2

multiple interactions

Ethylmaleimide inhibits the reaction [IL1A protein results in increased expression of SOD2 mRNA]; Ethylmaleimide inhibits the reaction [IL1A protein results in increased expression of SOD2 protein]; Ethylmaleimide inhibits the reaction [TNF protein results in increased expression of SOD2 mRNA]; Ethylmaleimide inhibits the reaction [TNF protein results in increased expression of SOD2 protein]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

Sp1 transcription factor

multiple interactions

Ethylmaleimide inhibits the reaction [CD 437 results in increased cleavage of SP1 protein]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

small ubiquitin-like modifier 2

multiple interactions

Ethylmaleimide inhibits the reaction [SUMO2 protein binds to SENP1 protein]; Ethylmaleimide inhibits the reaction [SUMO2 protein binds to SENP6 protein]

NCBI chr10:100,771,941...100,784,503
Ensembl chr10:100,686,797...100,784,513

G

transferrin

decreases uptake

Ethylmaleimide results in decreased uptake of TF protein

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

tyrosine hydroxylase

multiple interactions

Ethylmaleimide inhibits the reaction [Clozapine results in decreased expression of TH protein]

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

tumor necrosis factor

multiple interactions

Ethylmaleimide inhibits the reaction [TNF protein results in increased expression of SOD2 mRNA]; Ethylmaleimide inhibits the reaction [TNF protein results in increased expression of SOD2 protein]

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

voltage-dependent anion channel 1

affects binding

Ethylmaleimide binds to VDAC1 protein

NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640

pemetrexed

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 5

decreases response to substance

ABCC5 protein results in decreased susceptibility to Pemetrexed

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ALK receptor tyrosine kinase

affects response to substance

ALK gene mutant form affects the susceptibility to Pemetrexed

NCBI chr 6:22,879,653...23,599,636
Ensembl chr 6:22,880,625...23,598,034

G

Bcl-2 binding component 3

increases expression
multiple interactions

Pemetrexed results in increased expression of BBC3 protein
xanthohumol promotes the reaction [Pemetrexed results in increased expression of BBC3 protein]

NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509

G

BCL2, apoptosis regulator

multiple interactions

[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of BCL2 protein; [Cisplatin co-treated with Pemetrexed co-treated with Vorinostat] results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BH3 interacting domain death agonist

multiple interactions

[Cisplatin co-treated with Pemetrexed] results in increased cleavage of BID protein

NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720

G

complement C3

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 mRNA; [Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of C3 protein

NCBI chr 9:2,087,437...2,114,366
Ensembl chr 9:2,087,437...2,114,429

G

C-C motif chemokine ligand 2

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

cyclin D1

multiple interactions

[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in decreased expression of CCND1 protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in decreased expression of CCND1 protein

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[Cisplatin co-treated with Pemetrexed co-treated with Valproic Acid] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed co-treated with vorinostat] results in increased expression of CDKN1A protein; [Cisplatin co-treated with Pemetrexed] results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

CASP8 and FADD-like apoptosis regulator

decreases response to substance

CFLAR results in decreased susceptibility to Pemetrexed

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

DNA-damage inducible transcript 3

multiple interactions

DDIT3 mutant form inhibits the reaction [Pemetrexed results in increased expression of TNFRSF10B]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

dihydrofolate reductase

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of DHFR mRNA

NCBI chr 2:23,585,876...23,611,199
Ensembl chr 2:23,586,031...23,613,713

G

ERCC excision repair 1, endonuclease non-catalytic subunit

multiple interactions
decreases expression

Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 mRNA]; Pemetrexed inhibits the reaction [resveratrol results in increased stability of and results in increased expression of ERCC1 protein]
Pemetrexed results in decreased expression of ERCC1 mRNA; Pemetrexed results in decreased expression of ERCC1 protein

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

Fas cell surface death receptor

increases expression
multiple interactions

Pemetrexed results in increased expression of FAS protein
TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein]; TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

folylpolyglutamate synthase

increases response to substance

FPGS protein results in increased susceptibility to Pemetrexed

NCBI chr 3:15,972,800...15,993,592
Ensembl chr 3:15,972,800...15,993,563

G

gamma-glutamyl hydrolase

affects response to substance

GGH protein affects the susceptibility to Pemetrexed

NCBI chr 5:33,529,880...33,552,790
Ensembl chr 5:33,529,880...33,552,787

G

IFI30, lysosomal thiol reductase

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IFI30 mRNA

NCBI chr16:18,675,590...18,679,655
Ensembl chr16:18,675,613...18,681,175

G

interleukin 11

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL11 mRNA

NCBI chr 1:69,069,829...69,076,129
Ensembl chr 1:69,068,137...69,076,129

G

interleukin 13 receptor subunit alpha 2

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL13RA2 mRNA

NCBI chr X:111,002,590...111,074,053
Ensembl chr X:111,002,592...111,072,381

G

interleukin 1 alpha

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 receptor-like 1

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL1RL1 mRNA

NCBI chr 9:42,661,694...42,727,266
Ensembl chr 9:42,697,192...42,727,256

G

interleukin 33

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL33 mRNA

NCBI chr 1:227,701,964...227,736,374
Ensembl chr 1:227,721,435...227,736,373

G

interleukin 7 receptor

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of IL7R mRNA

NCBI chr 2:58,452,393...58,477,757
Ensembl chr 2:58,454,217...58,477,757

G

killer cell lectin like receptor C1

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of KLRC1 mRNA

NCBI chr 4:163,142,142...163,152,425
Ensembl chr 4:163,147,189...163,152,425

G

KRAS proto-oncogene, GTPase

decreases expression
increases response to substance

Pemetrexed results in decreased expression of KRAS mRNA; Pemetrexed results in decreased expression of KRAS mRNA mutant form; Pemetrexed results in decreased expression of KRAS protein
KRAS gene mutant form results in increased susceptibility to Pemetrexed

NCBI chr 4:178,185,418...178,218,484

G

methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase

increases response to substance

MTHFD2 protein results in increased susceptibility to Pemetrexed

NCBI chr 4:115,811,135...115,822,663
Ensembl chr 4:115,811,139...115,822,608

G

nucleophosmin 1

decreases response to substance

NPM1 protein results in decreased susceptibility to Pemetrexed

NCBI chr10:17,741,512...17,751,626
Ensembl chr10:17,739,941...17,751,645

G

NRAS proto-oncogene, GTPase

increases response to substance

NRAS gene mutant form results in increased susceptibility to Pemetrexed

NCBI chr 2:190,582,885...190,593,509
Ensembl chr 2:190,582,918...190,591,626

G

RNA binding motif protein 17

decreases response to substance

RBM17 protein results in decreased susceptibility to Pemetrexed

NCBI chr17:66,937,140...66,954,034
Ensembl chr17:66,937,140...66,954,014

G

solute carrier family 19 member 1

multiple interactions
increases response to substance

Pemetrexed inhibits the reaction [SLC19A1 protein results in increased transport of Methotrexate]
SLC19A1 exon mutant form results in increased susceptibility to Pemetrexed

PMID:16505119 PMID:21879757

NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972

G

solute carrier family 46 member 1

multiple interactions
increases activity
increases response to substance

Pemetrexed inhibits the reaction [SLC46A1 protein results in increased uptake of Methotrexate]
Pemetrexed results in increased activity of SLC46A1 protein
SLC46A1 protein results in increased susceptibility to Pemetrexed

NCBI chr10:63,361,504...63,367,940
Ensembl chr10:63,361,486...63,368,848

G

TNF alpha induced protein 3

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFAIP3 mRNA

NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282

G

TNF receptor superfamily member 9

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TNFRSF9 mRNA

NCBI chr 5:161,381,662...161,408,003
Ensembl chr 5:161,381,662...161,408,000

G

tumor protein p53

multiple interactions
affects response to substance

TP53 protein affects the reaction [Pemetrexed results in increased expression of FAS protein]
TP53 protein affects the susceptibility to Pemetrexed

PMID:15161716 PMID:17339891

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

TNF receptor-associated factor 1

multiple interactions

[Folic Acid affects the susceptibility to Pemetrexed] which affects the expression of TRAF1 mRNA

NCBI chr 3:18,222,024...18,242,163
Ensembl chr 3:18,222,054...18,241,807

G

thymidine phosphorylase

increases response to substance

TYMP protein results in increased susceptibility to Pemetrexed

NCBI chr 7:120,438,768...120,444,088
Ensembl chr 7:120,438,770...120,443,874
Ensembl chr 7:120,438,770...120,443,874

G

thymidylate synthetase

decreases activity
multiple interactions
affects response to substance

Pemetrexed results in decreased activity of TYMS protein
TYMS protein inhibits the reaction [Pemetrexed results in increased expression of FAS protein]
TYMS affects the susceptibility to Pemetrexed; TYMS protein affects the susceptibility to Pemetrexed

PMID:15161716 PMID:17339891 PMID:21742432

NCBI chr 9:113,313,454...113,329,551
Ensembl chr 9:113,313,452...113,329,536

S-adenosyl-L-homocysteine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adenosylhomocysteinase

increases hydrolysis

AHCY results in increased hydrolysis of S-Adenosylhomocysteine

NCBI chr 3:143,569,134...143,584,359
Ensembl chr 3:143,569,094...143,584,393

G

aryl hydrocarbon receptor

increases abundance
multiple interactions

AHR protein results in increased abundance of S-Adenosylhomocysteine
PEMT protein promotes the reaction [AHR protein results in increased abundance of S-Adenosylhomocysteine]

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

5'-aminolevulinate synthase 2

multiple interactions

[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of ALAS2 mRNA]

NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519

G

amyloid beta precursor protein

increases expression
decreases methylation
multiple interactions

S-Adenosylhomocysteine results in increased expression of APP protein
S-Adenosylhomocysteine results in decreased methylation of APP promoter
Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of APP promoter]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein]; S-Adenosylhomocysteine results in increased expression of and results in increased cleavage of APP protein

PMID:19635394 PMID:22064374

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

ATPase copper transporting beta

increases abundance

ATP7B protein mutant form results in increased abundance of S-Adenosylhomocysteine

NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636

G

beta-secretase 1

increases expression

S-Adenosylhomocysteine results in increased expression of BACE1 protein

NCBI chr 8:46,142,060...46,166,268
Ensembl chr 8:46,142,116...46,165,876

G

coactivator-associated arginine methyltransferase 1

decreases activity

S-Adenosylhomocysteine results in decreased activity of CARM1 protein

NCBI chr 8:20,097,262...20,141,950
Ensembl chr 8:20,097,254...20,147,689

G

collagen type I alpha 1 chain

decreases expression

S-Adenosylhomocysteine results in decreased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type I alpha 2 chain

decreases expression

S-Adenosylhomocysteine results in decreased expression of COL1A2 mRNA

NCBI chr 4:32,563,938...32,598,868
Ensembl chr 4:32,563,381...32,598,867

G

catechol-O-methyltransferase

decreases activity

S-Adenosylhomocysteine results in decreased activity of COMT protein

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

DNA methyltransferase 1

decreases activity
multiple interactions

S-Adenosylhomocysteine results in decreased activity of DNMT1 protein
S-Adenosylhomocysteine inhibits the reaction [DNMT1 protein binds to OGG1 promoter]

PMID:16037419 PMID:22064374

NCBI chr 8:19,440,611...19,486,659
Ensembl chr 8:19,440,611...19,486,659

G

fibroblast growth factor 19

decreases abundance

FGF19 protein results in decreased abundance of S-Adenosylhomocysteine

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

hemoglobin subunit beta

multiple interactions

[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HBB mRNA]

NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012

G

hydroxymethylbilane synthase

multiple interactions

[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA; catechol inhibits the reaction [[S-Adenosylhomocysteine co-treated with Hemin] results in increased expression of HMBS mRNA]

NCBI chr 8:44,673,554...44,680,950
Ensembl chr 8:44,673,554...44,680,957

G

matrix metallopeptidase 2

increases expression
multiple interactions

S-Adenosylhomocysteine results in increased expression of MMP2 mRNA; S-Adenosylhomocysteine results in increased expression of MMP2 protein
S-Adenosylhomocysteine promotes the reaction [SP1 protein binds to MMP2 promoter]
U 0126 inhibits the reaction [S-Adenosylhomocysteine results in increased expression of MMP2 protein]

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

NFKB inhibitor alpha

decreases expression

S-Adenosylhomocysteine results in decreased expression of NFKBIA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nuclear receptor subfamily 0, group B, member 2

decreases abundance

NR0B2 protein results in decreased abundance of S-Adenosylhomocysteine

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

8-oxoguanine DNA glycosylase

multiple interactions
decreases methylation
decreases expression

Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased expression of OGG1 protein]; Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of OGG1 promoter]; S-Adenosylhomocysteine inhibits the reaction [DNMT1 protein binds to OGG1 promoter]
S-Adenosylhomocysteine results in decreased expression of OGG1 mRNA; S-Adenosylhomocysteine results in decreased expression of OGG1 protein

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766

G

phosphatidylethanolamine N-methyltransferase

multiple interactions

PEMT protein promotes the reaction [AHR protein results in increased abundance of S-Adenosylhomocysteine]

NCBI chr10:44,775,910...44,849,990
Ensembl chr10:44,775,911...44,850,013

G

PPARG coactivator 1 alpha

increases expression

S-Adenosylhomocysteine results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein arginine methyltransferase 1

decreases activity

S-Adenosylhomocysteine results in decreased activity of PRMT1 protein

NCBI chr 1:95,458,853...95,468,176
Ensembl chr 1:95,458,850...95,468,345

G

protein arginine methyltransferase 5

decreases activity

S-Adenosylhomocysteine results in decreased activity of PRMT5 protein

NCBI chr15:27,968,893...27,978,291
Ensembl chr15:27,968,910...27,978,296

G

protein arginine methyltransferase 6

decreases activity

S-Adenosylhomocysteine results in decreased activity of PRMT6 protein

NCBI chr 2:197,927,750...197,932,760
Ensembl chr 2:197,927,220...197,933,648

G

protein arginine methyltransferase 7

decreases activity

S-Adenosylhomocysteine results in decreased activity of PRMT7 protein

NCBI chr19:34,110,724...34,161,531
Ensembl chr19:34,110,747...34,162,577

G

presenilin 1

multiple interactions
decreases methylation
increases expression

Betaine inhibits the reaction [S-Adenosylhomocysteine results in decreased methylation of PSEN1 promoter]
S-Adenosylhomocysteine results in increased expression of PSEN1 protein

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

G

solute carrier family 19 member 1

affects abundance

SLC19A1 protein affects the abundance of S-Adenosylhomocysteine

NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972

G

Sp1 transcription factor

multiple interactions

S-Adenosylhomocysteine promotes the reaction [SP1 protein binds to MMP2 promoter]

NCBI chr 7:133,541,302...133,571,961
Ensembl chr 7:133,541,491...133,571,961

G

TIMP metallopeptidase inhibitor 2

decreases expression

S-Adenosylhomocysteine results in decreased expression of TIMP2 protein

NCBI chr10:103,541,199...103,590,611
Ensembl chr10:103,531,505...103,590,611

tolcapone

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arylacetamide deacetylase

decreases expression

tolcapone results in decreased expression of AADAC mRNA

NCBI chr 2:144,163,436...144,186,086
Ensembl chr 2:144,135,319...144,174,734

G

alanyl-tRNA synthetase 1

increases expression

Tolcapone results in increased expression of AARS1 mRNA

NCBI chr19:38,999,130...39,021,152
Ensembl chr19:38,999,163...39,021,147

G

ATP binding cassette subfamily B member 11

decreases activity

tolcapone results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily D member 2

affects binding

tolcapone binds to ABCD2 protein

NCBI chr 7:122,263,034...122,311,642
Ensembl chr 7:122,263,032...122,311,642

G

abhydrolase domain containing 10, depalmitoylase

affects binding

tolcapone binds to ABHD10 protein

NCBI chr11:55,081,273...55,095,044
Ensembl chr11:55,081,049...55,107,866

G

acetyl-CoA acetyltransferase 2

increases expression

tolcapone results in increased expression of ACAT2 mRNA

NCBI chr 1:47,695,833...47,713,879
Ensembl chr 1:47,695,788...47,752,821

G

acyl-CoA oxidase 3, pristanoyl

affects binding

tolcapone binds to ACOX3 protein

NCBI chr14:75,133,986...75,176,767
Ensembl chr14:75,094,676...75,176,205

G

acyl-CoA synthetase long-chain family member 1

affects binding
decreases expression

tolcapone binds to ACSL1 protein
tolcapone results in decreased expression of ACSL1 mRNA; tolcapone results in decreased expression of ACSL1 protein

PMID:19783845 PMID:29688484

NCBI chr16:45,755,246...45,821,541
Ensembl chr16:45,755,254...45,821,541

G

acyl-CoA synthetase long-chain family member 5

decreases expression

tolcapone results in decreased expression of ACSL5 protein

NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:254,292,521...254,336,607

G

acyl-CoA synthetase short-chain family member 2

increases expression

tolcapone results in increased expression of ACSS2 mRNA

NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675

G

actin alpha 2, smooth muscle

affects binding

tolcapone binds to ACTA2 protein

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

ADP-ribosylhydrolase like 1

affects binding

tolcapone binds to ADPRHL1 protein

NCBI chr16:76,283,186...76,315,075
Ensembl chr16:76,283,103...76,354,440

G

aspartylglucosaminidase

decreases expression

tolcapone results in decreased expression of AGA mRNA

NCBI chr16:38,504,661...38,516,607
Ensembl chr16:38,504,663...38,516,606

G

allograft inflammatory factor 1

decreases expression

tolcapone results in decreased expression of AIF1 mRNA

NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668

G

adenylate kinase 2

affects binding

tolcapone binds to AK2 protein

NCBI chr 5:141,308,650...141,364,633
Ensembl chr 5:141,346,063...141,364,632

G

aldo-keto reductase family 1, member C1

affects binding

Tolcapone binds to AKR1C1 protein

NCBI chr17:65,810,474...65,837,385
Ensembl chr17:65,810,475...65,837,326

G

aldo-keto reductase family 1, member C3

decreases expression

tolcapone results in decreased expression of AKR1C3 mRNA

NCBI chr17:66,110,970...66,127,867
Ensembl chr17:66,110,963...66,127,873

G

aldo-keto reductase family 1, member D1

affects binding

tolcapone binds to AKR1D1 protein

NCBI chr 4:66,154,246...66,187,505
Ensembl chr 4:66,154,248...66,186,372

G

aldehyde dehydrogenase 18 family, member A1

affects binding

tolcapone binds to ALDH18A1 protein

NCBI chr 1:239,375,657...239,407,956
Ensembl chr 1:239,375,669...239,407,890

G

aldehyde dehydrogenase 1 family, member B1

affects binding

tolcapone binds to ALDH1B1 protein

NCBI chr 5:60,063,370...60,068,378
Ensembl chr 5:60,063,225...60,068,378

G

aldehyde dehydrogenase 1 family, member L1

increases expression

tolcapone results in increased expression of ALDH1L1 mRNA

NCBI chr 4:123,059,989...123,106,471
Ensembl chr 4:123,060,008...123,106,465

G

aldehyde dehydrogenase 3 family, member A2

affects binding

tolcapone binds to ALDH3A2 protein

NCBI chr10:45,928,313...45,949,366
Ensembl chr10:45,908,524...45,949,281

G

ALG13, UDP-N-acetylglucosaminyltransferase subunit

decreases expression

Tolcapone results in decreased expression of ALG13 mRNA

NCBI chr X:107,906,320...107,968,232
Ensembl chr X:107,885,093...107,942,695

G

autocrine motility factor receptor

increases expression

tolcapone results in increased expression of AMFR mRNA

NCBI chr19:10,996,705...11,032,260
Ensembl chr19:10,996,099...11,032,247

G

adipocyte plasma membrane associated protein

affects binding

tolcapone binds to APMAP protein

NCBI chr 3:139,409,021...139,437,296
Ensembl chr 3:139,409,022...139,437,341

G

apolipoprotein A1

affects binding

tolcapone binds to APOA1 protein

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein B

decreases expression
decreases secretion

tolcapone results in decreased expression of APOB mRNA
tolcapone results in decreased secretion of APOB protein alternative form

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein C2

decreases expression

tolcapone results in decreased expression of APOC2 mRNA

NCBI chr 1:79,329,429...79,334,397
Ensembl chr 1:79,329,428...79,334,476

G

apolipoprotein E

affects binding

tolcapone binds to APOE protein

NCBI chr 1:79,353,924...79,357,852
Ensembl chr 1:79,353,916...79,357,932

G

apolipoprotein O-like

decreases expression

tolcapone results in decreased expression of APOOL mRNA

NCBI chr X:77,377,723...77,443,672
Ensembl chr X:77,377,781...77,443,900

G

ADP-ribosylation factor 4

affects binding

tolcapone binds to ARF4 protein

NCBI chr16:1,896,692...1,913,267
Ensembl chr16:1,896,546...1,913,261

G

ADP-ribosylation factor like GTPase 1

affects binding

tolcapone binds to ARL1 protein

NCBI chr 7:23,120,004...23,131,173
Ensembl chr 7:23,119,589...23,131,898

G

ATPase family, AAA domain containing 1

affects binding

tolcapone binds to ATAD1 protein

NCBI chr 1:230,544,227...230,610,524
Ensembl chr 1:230,544,047...230,596,548

G

ATPase family, AAA domain containing 3A

affects binding

tolcapone binds to ATAD3A protein

NCBI chr 5:166,350,302...166,370,492
Ensembl chr 5:166,350,304...166,370,482

G

activating transcription factor 5

increases expression

tolcapone results in increased expression of ATF5 mRNA

NCBI chr 1:95,295,602...95,299,755
Ensembl chr 1:95,295,610...95,299,707

G

ATPase Na+/K+ transporting subunit beta 3

affects binding

tolcapone binds to ATP1B3 protein

NCBI chr 8:96,910,265...96,941,592
Ensembl chr 8:96,910,309...96,941,598

G

ATP synthase F1 subunit beta

affects binding

tolcapone binds to ATP5F1B protein

NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273

G

ATP synthase F1 subunit gamma

affects binding

Tolcapone binds to ATP5F1C protein

NCBI chr17:68,423,927...68,446,169
Ensembl chr17:68,423,909...68,608,367

G

ATP synthase F1 subunit epsilon

decreases expression

tolcapone results in decreased expression of ATP5F1E mRNA

NCBI chr 3:163,259,072...163,261,974
Ensembl chr 3:163,260,476...163,261,450

G

ATP synthase membrane subunit e

decreases expression
affects binding

tolcapone results in decreased expression of ATP5ME mRNA
tolcapone binds to ATP5ME protein

PMID:19783845 PMID:24136188

NCBI chr14:1,319,868...1,320,996
Ensembl chr14:1,319,868...1,321,013

G

ATP synthase membrane subunit f

affects binding

tolcapone binds to ATP5MF protein

NCBI chr12:9,421,665...9,428,236
Ensembl chr12:9,421,579...9,428,236

G

ATP synthase membrane subunit G

decreases expression
affects binding

tolcapone results in decreased expression of ATP5MG mRNA
tolcapone binds to ATP5MG protein

PMID:19783845 PMID:24136188

NCBI chr 8:45,225,680...45,233,630
Ensembl chr 8:45,225,686...45,233,559

G

ATP synthase membrane subunit K

decreases expression

Tolcapone results in decreased expression of ATP5MK mRNA

NCBI chr 1:245,973,910...245,980,702
Ensembl chr 1:245,973,914...245,980,761
Ensembl chr10:245,973,914...245,980,761

G

ATP synthase peripheral stalk subunit F6

decreases expression

tolcapone results in decreased expression of ATP5PF mRNA

NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119

G

ATP synthase peripheral stalk subunit OSCP

affects binding

tolcapone binds to ATP5PO protein

NCBI chr11:31,165,218...31,171,530
Ensembl chr11:31,165,217...31,171,592

G

AU RNA binding methylglutaconyl-CoA hydratase

affects binding

tolcapone binds to AUH protein

NCBI chr17:12,329,522...12,424,882
Ensembl chr17:12,329,524...12,424,896

G

gamma-butyrobetaine hydroxylase 1

decreases expression

tolcapone results in decreased expression of BBOX1 mRNA

NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458

G

basal cell adhesion molecule (Lutheran blood group)

affects binding

tolcapone binds to BCAM protein

NCBI chr 1:79,415,016...79,429,403
Ensembl chr 1:79,415,017...79,429,403

G

B-cell receptor-associated protein 29

decreases expression

tolcapone results in decreased expression of BCAP29 mRNA

NCBI chr 6:48,182,702...48,222,698
Ensembl chr 6:48,182,706...48,222,720

G

BCAS2, pre-mRNA processing factor

decreases expression

tolcapone results in decreased expression of BCAS2 mRNA

NCBI chr 2:190,692,503...190,700,386
Ensembl chr 2:190,692,461...190,700,389

G

bridge-like lipid transfer protein family member 1

increases expression

Tolcapone results in increased expression of BLTP1 mRNA

NCBI chr 2:119,708,114...119,924,697
Ensembl chr 2:119,708,209...119,924,695

G

BMP-binding endothelial regulator

affects binding

tolcapone binds to BMPER protein

NCBI chr 8:21,732,225...21,977,261
Ensembl chr 8:21,732,225...21,977,256

G

BMS1 ribosome biogenesis factor

affects binding

tolcapone binds to BMS1 protein

NCBI chr 4:151,558,163...151,595,187
Ensembl chr 4:151,558,163...151,595,127

G

bisphosphoglycerate mutase

decreases expression

tolcapone results in decreased expression of BPGM mRNA

NCBI chr 4:63,139,730...63,168,581
Ensembl chr 4:63,140,018...63,168,581

G

basic transcription factor 3-like 4

decreases expression

tolcapone results in decreased expression of BTF3L4 mRNA

NCBI chr 5:123,567,902...123,587,527
Ensembl chr 5:123,567,907...123,586,866

G

C1D nuclear receptor corepressor

decreases expression

tolcapone results in decreased expression of C1D mRNA

NCBI chr14:91,660,951...91,673,177
Ensembl chr14:91,660,989...91,672,852

G

C1GALT1-specific chaperone 1

decreases expression

tolcapone results in decreased expression of C1GALT1C1 mRNA

NCBI chr X:117,378,123...117,382,620
Ensembl chr X:117,375,525...117,382,787

G

complement C4B

increases expression

tolcapone results in increased expression of C4B mRNA

NCBI chr20:4,197,371...4,211,684
Ensembl chr20:4,197,366...4,211,681

G

complement C5

increases expression

tolcapone results in increased expression of C5 mRNA

NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994

G

complement C8 alpha chain

increases expression

tolcapone results in increased expression of C8A mRNA

NCBI chr 5:119,583,168...119,637,675
Ensembl chr 5:119,583,174...119,637,754

G

similar to human chromosome 11 open reading frame 71

decreases expression

Tolcapone results in decreased expression of C8H11ORF71 mRNA

NCBI chr 8:48,838,556...48,838,970
Ensembl chr 8:48,838,100...48,842,270

G

similar to human chromosome 15 open reading frame 61

decreases expression

Tolcapone results in decreased expression of C8H15ORF61 mRNA

NCBI chr 8:63,868,125...63,872,863
Ensembl chr 8:63,868,125...63,872,751

G

carbonyl reductase 4

decreases expression

tolcapone results in decreased expression of CBR4 mRNA

NCBI chr16:28,629,928...28,684,230
Ensembl chr16:28,617,224...28,645,712

G

cyclin L2

increases expression

tolcapone results in increased expression of CCNL2 mRNA

NCBI chr 5:166,416,940...166,428,997
Ensembl chr 5:166,417,508...166,436,882

G

chaperonin containing TCP1 subunit 7

affects binding

tolcapone binds to CCT7 protein

NCBI chr 4:117,989,232...118,006,478
Ensembl chr 4:117,989,232...118,006,580

G

CD36 molecule

increases expression

tolcapone results in increased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

complement factor B

increases expression

tolcapone results in increased expression of CFB mRNA

NCBI chr20:3,970,643...3,976,510
Ensembl chr20:3,951,474...3,976,505

G

coiled-coil-helix-coiled-coil-helix domain containing 1

decreases expression

tolcapone results in decreased expression of CHCHD1 mRNA

NCBI chr15:3,592,719...3,593,901
Ensembl chr15:3,592,727...3,593,901

G

coiled-coil-helix-coiled-coil-helix domain containing 7

decreases expression

tolcapone results in decreased expression of CHCHD7 mRNA

NCBI chr 5:16,957,127...16,961,682
Ensembl chr 5:16,957,188...16,961,184

G

chromatin accessibility complex subunit 1

decreases expression

tolcapone results in decreased expression of CHRAC1 mRNA

NCBI chr 7:105,013,047...105,016,435
Ensembl chr 7:105,013,015...105,017,136

G

churchill domain containing 1

decreases expression

tolcapone results in decreased expression of CHURC1 mRNA

NCBI chr 6:95,464,488...95,485,208
Ensembl chr 6:95,470,683...95,619,586

G

cytosolic iron-sulfur assembly component 2A

decreases expression

tolcapone results in decreased expression of CIAO2A mRNA

NCBI chr 8:66,670,533...66,682,455
Ensembl chr 8:66,670,483...66,682,455

G

cell death-inducing DFFA-like effector a

increases expression

tolcapone results in increased expression of CIDEA mRNA

NCBI chr18:60,894,917...60,920,485
Ensembl chr18:60,894,874...60,920,481

G

CDGSH iron sulfur domain 1

affects binding

tolcapone binds to CISD1 protein

NCBI chr20:17,255,302...17,268,688
Ensembl chr20:17,255,151...17,284,924

G

C-type lectin domain family 4, member A3

decreases expression

Tolcapone results in decreased expression of CLEC4A3 mRNA

NCBI chr 4:156,214,030...156,224,818
Ensembl chr 4:156,214,718...156,224,817

G

clathrin heavy chain

affects binding

tolcapone binds to CLTC protein

NCBI chr10:71,517,661...71,574,591
Ensembl chr10:71,517,663...71,573,737

G

cornichon family member 4

decreases expression

tolcapone results in decreased expression of CNIH4 mRNA

NCBI chr13:92,910,315...92,926,428
Ensembl chr13:92,910,315...92,927,853

G

COMM domain containing 6

decreases expression

tolcapone results in decreased expression of COMMD6 mRNA

NCBI chr15:78,467,333...78,474,382
Ensembl chr15:78,467,804...78,474,382

G

catechol-O-methyltransferase

decreases activity
multiple interactions
increases methylation
affects binding

tolcapone results in decreased activity of COMT protein
[tolcapone results in decreased activity of COMT protein] inhibits the reaction [Levodopa results in increased abundance of Homocysteine]; [tolcapone results in decreased activity of COMT protein] inhibits the reaction [Levodopa results in increased abundance of S-Adenosylmethionine]; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Adenosine Triphosphate; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Homovanillic Acid; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of 3,4-Dihydroxyphenylacetic Acid; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Epinephrine; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Levodopa; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Norepinephrine; tolcapone inhibits the reaction [COMT protein results in increased methylation of Levodopa]
[tolcapone results in decreased activity of COMT protein] promotes the reaction [Clozapine results in increased abundance of Dopamine]; [tolcapone results in decreased activity of COMT protein] which results in decreased abundance of Homovanillic Acid; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of 3,4-Dihydroxyphenylacetic Acid; tolcapone inhibits the reaction [[COMT protein results in increased methylation of Epinephrine] which results in increased abundance of Metanephrine]
COMT protein results in increased methylation of tolcapone
tolcapone binds to COMT protein

PMID:2089102 PMID:7566641 PMID:7768073 PMID:8821542 PMID:9333106 More...

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

COPI coat complex subunit gamma 1

affects binding

tolcapone binds to COPG1 protein

NCBI chr 4:120,366,540...120,392,502
Ensembl chr 4:120,366,542...120,415,616

G

COPI coat complex subunit gamma 2

decreases expression

tolcapone results in decreased expression of COPG2 mRNA

NCBI chr 4:59,366,086...59,501,591
Ensembl chr 4:59,366,086...59,501,618

G

coenzyme Q10A

decreases expression

tolcapone results in decreased expression of COQ10A mRNA

NCBI chr 7:792,089...798,392
Ensembl chr 7:792,089...800,161

G

coenzyme Q3 methyltransferase

decreases expression

tolcapone results in decreased expression of COQ3 mRNA

NCBI chr 5:35,429,567...35,460,613
Ensembl chr 5:35,429,574...35,460,607

G

cytochrome c oxidase subunit 6C

affects binding
decreases expression

tolcapone binds to COX6C protein
tolcapone results in decreased expression of COX6C mRNA

PMID:19783845 PMID:24136188

NCBI chr 7:67,129,265...67,142,001
Ensembl chr 7:67,111,024...67,141,963

G

cytochrome c oxidase subunit 7A2

decreases expression

tolcapone results in decreased expression of COX7A2 mRNA

NCBI chr 8:80,716,824...80,720,922
Ensembl chr14:51,301,168...51,301,633
Ensembl chr 8:51,301,168...51,301,633

G

cytochrome c oxidase subunit 7B

decreases expression

tolcapone results in decreased expression of COX7B mRNA

NCBI chr X:71,083,486...71,089,733
Ensembl chr X:71,083,456...71,089,732

G

ceruloplasmin

increases expression

tolcapone results in increased expression of CP mRNA

NCBI chr 2:102,439,433...102,498,075
Ensembl chr 2:102,439,624...102,498,075

G

cAMP responsive element modulator

decreases expression

tolcapone results in decreased expression of CREM mRNA

NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989

G

cysteine-rich protein 2

increases expression

tolcapone results in increased expression of CRIP2 mRNA

NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065

G

chromosome segregation 1 like

affects binding

tolcapone binds to CSE1L protein

NCBI chr 3:155,641,104...155,678,866
Ensembl chr 3:155,641,166...155,678,865

G

cystatin B

decreases expression

tolcapone results in decreased expression of CSTB mRNA

NCBI chr20:10,245,462...10,247,505
Ensembl chr20:10,245,462...10,247,526

G

cytochrome c-1

affects binding

tolcapone binds to CYC1 protein

NCBI chr 7:108,067,106...108,069,483
Ensembl chr 7:108,067,115...108,069,479

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
decreases activity

tolcapone inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
Tolcapone results in decreased activity of CYP1A1 protein

PMID:18493746 PMID:33814510

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression

tolcapone inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]
tolcapone results in increased expression of CYP1A2 mRNA

PMID:18493746 PMID:24136188

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Tolcapone results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases response to substance

CYP3A4 protein results in increased susceptibility to Tolcapone

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 51

increases expression

tolcapone results in increased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410

G

death-associated protein

increases expression

tolcapone results in increased expression of DAP mRNA

NCBI chr 2:82,199,206...82,251,771
Ensembl chr 2:82,199,280...82,251,752

G

dCMP deaminase

affects binding

tolcapone binds to DCTD protein

NCBI chr16:44,066,952...44,098,654
Ensembl chr16:44,055,128...44,098,446

G

dolichyl-diphosphooligosaccharide--protein glycosyltransferase non-catalytic subunit

affects binding

tolcapone binds to DDOST protein

NCBI chr 5:150,522,297...150,529,413
Ensembl chr 5:150,522,242...150,529,413

G

DEAD-box helicase 18

affects binding

tolcapone binds to DDX18 protein

NCBI chr13:32,729,697...32,743,161
Ensembl chr13:32,729,700...32,743,161

G

24-dehydrocholesterol reductase

affects binding
increases expression

tolcapone binds to DHCR24 protein
tolcapone results in increased expression of DHCR24 mRNA

PMID:19783845 PMID:24136188

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

7-dehydrocholesterol reductase

affects binding

tolcapone binds to DHCR7 protein

NCBI chr 1:199,015,081...199,031,055
Ensembl chr 1:199,015,081...199,031,055

G

distal membrane arm assembly component 1

decreases expression

tolcapone results in decreased expression of DMAC1 mRNA

NCBI chr 5:89,241,173...89,243,793
Ensembl chr 5:89,242,661...89,243,757

G

DnaJ heat shock protein family (Hsp40) member C15

decreases expression

tolcapone results in decreased expression of DNAJC15 mRNA

NCBI chr15:53,182,060...53,249,675
Ensembl chr15:53,184,855...53,249,675

G

dedicator of cytokinesis 11

decreases expression

tolcapone results in decreased expression of DOCK11 mRNA

NCBI chr X:115,131,720...115,314,854
Ensembl chr X:115,131,909...115,314,854

G

dolichyl-phosphate mannosyltransferase subunit 3, regulatory

decreases expression

tolcapone results in decreased expression of DPM3 mRNA

NCBI chr 2:174,676,532...174,677,047
Ensembl chr 2:174,676,363...174,677,668
Ensembl chr15:174,676,363...174,677,668

G

dpy-30 histone methyltransferase complex regulatory subunit

decreases expression

tolcapone results in decreased expression of DPY30 mRNA

NCBI chr 6:21,120,947...21,141,720
Ensembl chr 6:21,120,947...21,141,432

G

deoxythymidylate kinase

decreases expression

tolcapone results in decreased expression of DTYMK mRNA

NCBI chr 9:94,315,552...94,324,386
Ensembl chr 9:94,315,552...94,324,870

G

dynein light chain LC8-type 1

decreases expression

tolcapone results in decreased expression of DYNLL1 mRNA

NCBI chr12:41,312,365...41,316,157
Ensembl chr12:41,312,367...41,314,741

G

dynein light chain Tctex-type 3

decreases expression

tolcapone results in decreased expression of DYNLT3 mRNA

NCBI chr X:13,327,933...13,337,139
Ensembl chr X:13,327,892...13,337,139

G

EBP, cholestenol delta-isomerase

increases expression

tolcapone results in increased expression of EBP mRNA

NCBI chr X:14,299,427...14,305,826
Ensembl chr X:14,299,448...14,305,826

G

enoyl-CoA hydratase, short chain 1

affects binding

tolcapone binds to ECHS1 protein

NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884

G

elongin C

decreases expression

tolcapone results in decreased expression of ELOC mRNA

NCBI chr 5:2,661,527...2,677,893
Ensembl chr 5:2,661,724...2,677,890

G

epiregulin

decreases expression

Tolcapone results in decreased expression of EREG mRNA

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

coagulation factor V

increases expression

tolcapone results in increased expression of F5 mRNA

NCBI chr13:76,513,509...76,583,106
Ensembl chr13:76,513,255...76,582,317

G

family with sequence similarity 162, member A

affects binding

tolcapone binds to FAM162A protein

NCBI chr11:64,680,978...64,709,865
Ensembl chr11:64,680,323...64,711,239

G

fibrillarin-like 1

affects binding

tolcapone binds to FBLL1 protein

NCBI chr10:20,258,656...20,260,299
Ensembl chr10:20,258,656...20,260,299

G

Fcf1 rRNA-processing protein

decreases expression

tolcapone results in decreased expression of FCF1 mRNA

NCBI chr 6:104,617,780...104,629,643
Ensembl chr 6:104,617,770...104,629,643

G

fibrinogen alpha chain

affects binding

tolcapone binds to FGA protein

NCBI chr 2:168,374,120...168,381,523
Ensembl chr 2:168,374,120...168,381,528

G

formation of mitochondrial complex V assembly factor 1

decreases expression

tolcapone results in decreased expression of FMC1 mRNA

NCBI chr 4:67,274,104...67,282,140
Ensembl chr 4:67,274,104...67,282,140

G

glutaryl-CoA dehydrogenase

affects binding

tolcapone binds to GCDH protein

NCBI chr19:23,263,215...23,269,689
Ensembl chr19:23,263,264...23,269,681

G

golgi glycoprotein 1

affects binding

tolcapone binds to GLG1 protein

NCBI chr19:39,124,892...39,224,178
Ensembl chr19:39,124,641...39,224,178

G

glia maturation factor, gamma

decreases expression

tolcapone results in decreased expression of GMFG mRNA

NCBI chr 1:83,728,797...83,739,189
Ensembl chr 1:83,728,776...83,739,183

G

G protein subunit gamma 10

decreases expression

tolcapone results in decreased expression of GNG10 mRNA

NCBI chr 5:73,856,124...73,863,017
Ensembl chr 5:73,856,164...73,863,012
Ensembl chr 5:73,856,164...73,863,012

G

G protein subunit gamma 5

decreases expression

tolcapone results in decreased expression of GNG5 mRNA

NCBI chr 2:235,394,680...235,403,177
Ensembl chr 1:77,292,043...77,292,513

G

glypican 3

affects binding

tolcapone binds to GPC3 protein

NCBI chr X:131,868,986...132,236,824
Ensembl chr X:131,868,990...132,236,798

G

general transcription factor IIH subunit 5

decreases expression

tolcapone results in decreased expression of GTF2H5 mRNA

NCBI chr 1:46,656,804...46,663,512
Ensembl chr 1:46,656,859...46,664,939

G

H2A.Z variant histone 2

affects binding

Tolcapone binds to H2AZ2 protein

NCBI chr14:81,293,304...81,312,209
Ensembl chr14:81,293,299...81,312,144

G

hemoglobin subunit beta

affects binding

tolcapone binds to HBB protein

NCBI chr 1:158,250,421...158,251,832
Ensembl chr 1:158,120,200...158,252,012

G

HIG1 hypoxia inducible domain family, member 1A

decreases expression

tolcapone results in decreased expression of HIGD1A mRNA

NCBI chr 8:121,514,152...121,523,382
Ensembl chr 8:121,514,156...121,523,443

G

histidine triad nucleotide binding protein 3

decreases expression

tolcapone results in decreased expression of HINT3 mRNA

NCBI chr 1:27,035,936...27,045,799
Ensembl chr 1:27,035,905...27,047,721

G

histone cluster 1 H4 family member B

decreases expression

Tolcapone results in decreased expression of HIST1H4B mRNA

NCBI chr17:42,480,467...42,484,912
Ensembl chr17:42,480,313...42,485,370

G

heterogeneous nuclear ribonucleoprotein H1

affects binding

tolcapone binds to HNRNPH1 protein

NCBI chr10:34,692,868...34,702,849
Ensembl chr10:34,693,555...34,702,846

G

hydroxysteroid (17-beta) dehydrogenase 11

affects binding

tolcapone binds to HSD17B11 protein

NCBI chr14:5,693,304...5,743,157
Ensembl chr14:5,711,964...5,743,161

G

hydroxysteroid (17-beta) dehydrogenase 12

affects binding

tolcapone binds to HSD17B12 protein

NCBI chr 3:79,990,048...80,113,556
Ensembl chr 3:79,990,056...80,113,617

G

hydroxysteroid (17-beta) dehydrogenase 13

affects binding

tolcapone binds to HSD17B13 protein

NCBI chr14:5,751,697...5,766,809
Ensembl chr14:5,752,132...5,768,166

G

hydroxysteroid (17-beta) dehydrogenase 4

affects binding

tolcapone binds to HSD17B4 protein

NCBI chr18:43,328,903...43,417,950
Ensembl chr18:43,328,824...43,417,952

G

hydroxysteroid dehydrogenase like 2

increases expression

tolcapone results in increased expression of HSDL2 mRNA

NCBI chr 5:74,443,933...74,479,104
Ensembl chr 5:74,443,872...74,479,839

G

intraflagellar transport associated protein

decreases expression

Tolcapone results in decreased expression of IFTAP mRNA

NCBI chr 3:87,812,068...87,906,517
Ensembl chr 3:87,817,408...87,906,547

G

insulin-like growth factor binding protein 1

increases expression

tolcapone results in increased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

interleukin 24

decreases expression

Tolcapone results in decreased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

importin 7

affects binding

tolcapone binds to IPO7 protein

NCBI chr 1:164,062,702...164,102,938
Ensembl chr 1:164,062,702...164,102,938

G

integral membrane protein 2A

affects binding

tolcapone binds to ITM2A protein

NCBI chr X:72,486,383...72,492,344
Ensembl chr X:72,486,381...72,492,363

G

jagunal homolog 1

affects binding

tolcapone binds to JAGN1 protein

NCBI chr 4:146,591,577...146,596,287
Ensembl chr 4:146,591,510...146,596,288

G

potassium voltage-gated channel subfamily H member 2

decreases activity

tolcapone results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

alpha-ketoglutarate dehydrogenase subunit 4

decreases expression

Tolcapone results in decreased expression of KGD4 mRNA

NCBI chr 2:31,870,549...31,878,335
Ensembl chr 2:31,870,551...31,880,730

G

kininogen 1

increases expression

Tolcapone results in increased expression of KNG1 mRNA

NCBI chr11:77,812,757...77,835,555
Ensembl chr11:77,812,752...77,835,555

G

L antigen family, member 3

decreases expression

tolcapone results in decreased expression of LAGE3 mRNA

NCBI chr X:152,138,209...152,139,632
Ensembl chr X:152,138,218...152,139,632

G

lipopolysaccharide binding protein

increases expression

tolcapone results in increased expression of LBP mRNA

NCBI chr 3:146,953,889...146,981,032
Ensembl chr 3:146,954,015...146,981,586

G

leucine rich repeat containing 59

affects binding

tolcapone binds to LRRC59 protein

NCBI chr10:79,572,295...79,586,953
Ensembl chr10:79,572,317...79,602,533

G

LSM3 homolog, U6 small nuclear RNA and mRNA degradation associated

decreases expression

tolcapone results in decreased expression of LSM3 mRNA

NCBI chr 4:124,021,023...124,027,269
Ensembl chr 4:124,021,023...124,027,269

G

LSM5 homolog, U6 small nuclear RNA and mRNA degradation associated

decreases expression

tolcapone results in decreased expression of LSM5 mRNA

NCBI chr 4:85,951,073...85,954,289
Ensembl chr 6:104,652,477...104,654,165
Ensembl chr 4:104,652,477...104,654,165

G

LSM7 homolog, U6 small nuclear RNA and mRNA degradation associated

decreases expression

tolcapone results in decreased expression of LSM7 mRNA

NCBI chr 7:8,856,698...8,859,113
Ensembl chr 7:8,856,489...8,859,119

G

mago homolog, exon junction complex subunit

decreases expression

tolcapone results in decreased expression of MAGOH mRNA

NCBI chr 5:122,639,268...122,646,650
Ensembl chr 5:122,639,308...122,646,617

G

MBL associated serine protease 1

increases expression

tolcapone results in increased expression of MASP1 mRNA

NCBI chr11:77,334,794...77,405,271
Ensembl chr11:77,334,859...77,402,974

G

matrin 3

decreases expression

tolcapone results in decreased expression of MATR3 mRNA

NCBI chr18:27,154,098...27,193,212
Ensembl chr18:27,163,714...27,193,166

G

methylmalonyl CoA epimerase

decreases expression

tolcapone results in decreased expression of MCEE mRNA

NCBI chr 1:117,964,576...117,987,779
Ensembl chr 1:117,964,576...117,988,484

G

MCTS1, re-initiation and release factor

decreases expression

tolcapone results in decreased expression of MCTS1 mRNA

NCBI chr X:117,350,723...117,362,504
Ensembl chr X:117,350,889...117,362,504

G

mediator complex subunit 21

decreases expression

tolcapone results in decreased expression of MED21 mRNA

NCBI chr 4:179,560,509...179,583,811
Ensembl chr 4:179,560,579...179,567,548

G

mediator complex subunit 28

decreases expression

tolcapone results in decreased expression of MED28 mRNA

NCBI chr14:65,594,785...65,603,583
Ensembl chr14:65,594,647...65,603,583

G

mediator complex subunit 31

decreases expression

tolcapone results in decreased expression of MED31 mRNA

NCBI chr10:56,836,944...56,840,326
Ensembl chr10:56,836,944...56,840,326

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

Tolcapone results in increased expression of MET mRNA

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

methyltransferase 5, N6-adenosine

decreases expression

tolcapone results in decreased expression of METTL5 mRNA

NCBI chr 3:54,625,790...54,638,066
Ensembl chr 3:54,625,793...54,638,039

G

major facilitator superfamily domain containing 5

decreases expression

tolcapone results in decreased expression of MFSD5 mRNA

NCBI chr 7:133,409,096...133,411,377
Ensembl chr 7:133,402,537...133,411,396

G

microsomal glutathione S-transferase 1

affects binding

tolcapone binds to MGST1 protein

NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892

G

MIA SH3 domain ER export factor 3

decreases expression

tolcapone results in decreased expression of MIA3 mRNA

NCBI chr13:94,970,421...95,012,071
Ensembl chr13:94,970,424...95,011,972

G

MKKS centrosomal shuttling protein

decreases expression

tolcapone results in decreased expression of MKKS mRNA

NCBI chr 3:124,201,877...124,221,142
Ensembl chr 3:124,201,877...124,220,162

G

makorin ring finger protein 1

decreases expression

tolcapone results in decreased expression of MKRN1 mRNA

NCBI chr 4:68,175,908...68,197,216
Ensembl chr 4:68,175,909...68,197,165

G

metabolism of cobalamin associated D

decreases expression

tolcapone results in decreased expression of MMADHC mRNA

NCBI chr 3:34,708,649...34,726,554
Ensembl chr 3:34,708,649...34,726,771

G

mitochondrial ribosomal protein L1

decreases expression

tolcapone results in decreased expression of MRPL1 mRNA

NCBI chr14:13,300,522...13,359,654
Ensembl chr14:13,300,522...13,359,721

G

mitochondrial ribosomal protein L13

decreases expression

tolcapone results in decreased expression of MRPL13 mRNA

NCBI chr 7:86,951,541...86,973,147
Ensembl chr 7:86,951,541...86,973,577

G

mitochondrial ribosomal protein L14

decreases expression

tolcapone results in decreased expression of MRPL14 mRNA

NCBI chr 9:15,302,840...15,315,195
Ensembl chr 9:15,302,427...15,315,267

G

mitochondrial ribosomal protein L18

decreases expression

tolcapone results in decreased expression of MRPL18 mRNA

NCBI chr 1:47,837,169...47,841,987
Ensembl chr 1:47,836,561...47,841,987

G

mitochondrial ribosomal protein L20

decreases expression

tolcapone results in decreased expression of MRPL20 mRNA

NCBI chr 5:166,408,962...166,413,492
Ensembl chr 5:166,408,962...166,413,492

G

mitochondrial ribosomal protein L22

decreases expression

tolcapone results in decreased expression of MRPL22 mRNA

NCBI chr10:42,345,446...42,355,779
Ensembl chr10:42,342,776...42,355,779

G

mitochondrial ribosomal protein L23

decreases expression

tolcapone results in decreased expression of MRPL23 mRNA

NCBI chr 1:197,687,452...197,695,222
Ensembl chr 1:197,687,347...197,695,222

G

mitochondrial ribosomal protein L30

decreases expression

tolcapone results in decreased expression of MRPL30 mRNA

NCBI chr 9:40,125,352...40,136,189
Ensembl chr 9:40,125,430...40,137,257

G

mitochondrial ribosomal protein L32

decreases expression

tolcapone results in decreased expression of MRPL32 mRNA

NCBI chr17:50,565,133...50,568,000
Ensembl chr17:50,565,055...50,568,010

G

mitochondrial ribosomal protein L36

decreases expression

tolcapone results in decreased expression of MRPL36 mRNA

NCBI chr 1:29,965,481...29,968,896
Ensembl chr 1:29,965,317...29,968,807

G

mitochondrial ribosomal protein L40

decreases expression

tolcapone results in decreased expression of MRPL40 mRNA

NCBI chr11:82,133,398...82,139,234
Ensembl chr11:82,133,398...82,139,233

G

mitochondrial ribosomal protein L53

decreases expression

tolcapone results in decreased expression of MRPL53 mRNA

NCBI chr 4:115,615,329...115,616,219

G

mitochondrial ribosomal protein S14

decreases expression

tolcapone results in decreased expression of MRPS14 mRNA

NCBI chr13:72,429,168...72,434,915
Ensembl chr13:72,408,558...72,434,915

G

mitochondrial ribosomal protein S18C

decreases expression

tolcapone results in decreased expression of MRPS18C mRNA

NCBI chr14:8,812,301...8,818,538
Ensembl chr14:8,791,330...8,818,516

G

mitochondrial ribosomal protein S24

decreases expression

tolcapone results in decreased expression of MRPS24 mRNA

NCBI chr14:80,584,671...80,588,801
Ensembl chr14:80,584,673...80,588,871

G

mitochondrial ribosomal protein S33

decreases expression

tolcapone results in decreased expression of MRPS33 mRNA

NCBI chr 4:68,596,729...68,605,547
Ensembl chr 4:68,596,729...68,605,428

G

methylthioadenosine phosphorylase

affects binding

tolcapone binds to MTAP protein

NCBI chr 5:103,874,460...103,920,684
Ensembl chr 5:103,873,020...103,939,406

G

microsomal triglyceride transfer protein

increases expression

tolcapone results in increased expression of MTTP protein

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

mevalonate kinase

increases expression

tolcapone results in increased expression of MVK mRNA

NCBI chr12:42,141,391...42,158,893
Ensembl chr12:42,141,384...42,158,882

G

N(alpha)-acetyltransferase 20, NatB catalytic subunit

decreases expression

tolcapone results in decreased expression of NAA20 mRNA

NCBI chr 3:133,322,036...133,336,843
Ensembl chr 3:133,322,064...133,337,009

G

N-acetyltransferase 10

affects binding

tolcapone binds to NAT10 protein

NCBI chr 3:90,111,643...90,149,891
Ensembl chr 3:90,111,645...90,149,927

G

NADH:ubiquinone oxidoreductase subunit A1

decreases expression

tolcapone results in decreased expression of NDUFA1 mRNA

NCBI chr X:116,424,223...116,427,875
Ensembl chr X:116,424,223...116,428,633

G

NADH:ubiquinone oxidoreductase subunit A2

decreases expression

tolcapone results in decreased expression of NDUFA2 mRNA

NCBI chr18:28,355,774...28,357,863
Ensembl chr18:28,355,774...28,358,076

G

NADH:ubiquinone oxidoreductase subunit A6

decreases expression

tolcapone results in decreased expression of NDUFA6 mRNA

NCBI chr 7:113,866,382...113,870,239
Ensembl chr 7:113,866,382...113,870,239

G

NADH:ubiquinone oxidoreductase subunit A7

decreases expression

tolcapone results in decreased expression of NDUFA7 mRNA

NCBI chr 7:14,609,283...14,622,064
Ensembl chr 7:14,609,146...14,631,976

G

NADH:ubiquinone oxidoreductase subunit A9

affects binding

tolcapone binds to NDUFA9 protein

NCBI chr 4:159,659,242...159,688,034
Ensembl chr 4:159,659,242...159,688,018

G

NADH:ubiquinone oxidoreductase subunit B6

decreases expression

tolcapone results in decreased expression of NDUFB6 mRNA

NCBI chr 5:55,400,543...55,410,110
Ensembl chr 5:55,400,543...55,410,181

G

NADH:ubiquinone oxidoreductase subunit C2

decreases expression

tolcapone results in decreased expression of NDUFC2 mRNA

NCBI chr 1:151,711,965...151,718,188
Ensembl chr 1:151,711,901...151,718,189

G

NADH:ubiquinone oxidoreductase subunit S4

decreases expression

tolcapone results in decreased expression of NDUFS4 mRNA

NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846

G

NADH:ubiquinone oxidoreductase subunit S5

decreases expression

tolcapone results in decreased expression of NDUFS5 mRNA

NCBI chr 5:135,974,029...135,979,705
Ensembl chr 5:135,974,034...135,979,603
Ensembl chr14:135,974,034...135,979,603
Ensembl chr 2:135,974,034...135,979,603

G

NFE2 like bZIP transcription factor 2

decreases expression

tolcapone results in decreased expression of NFE2L2 mRNA

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nipsnap homolog 1

affects binding

tolcapone binds to NIPSNAP1 protein

NCBI chr14:79,734,234...79,758,101
Ensembl chr14:79,734,209...79,758,098

G

nipsnap homolog 2

affects binding

tolcapone binds to NIPSNAP2 protein

NCBI chr12:26,906,068...26,944,201
Ensembl chr12:26,911,723...26,944,166

G

NME/NM23 nucleoside diphosphate kinase 3

decreases expression

tolcapone results in decreased expression of NME3 mRNA

NCBI chr10:13,917,309...13,918,415
Ensembl chr10:13,917,403...13,918,359

G

NOP56 ribonucleoprotein

affects binding

tolcapone binds to NOP56 protein

NCBI chr 3:117,476,963...117,481,847
Ensembl chr 3:117,477,053...117,481,841

G

nephrocystin 1

decreases expression

tolcapone results in decreased expression of NPHP1 mRNA

NCBI chr 3:114,960,650...115,016,234
Ensembl chr 3:114,960,650...115,016,234

G

NPL4 homolog, ubiquitin recognition factor

increases expression

tolcapone results in increased expression of NPLOC4 mRNA

NCBI chr10:105,654,395...105,709,958
Ensembl chr10:105,654,812...105,709,913

G

nuclear receptor subfamily 3, group C, member 1

decreases expression

tolcapone results in decreased expression of NR3C1 mRNA

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

nuclear protein 2, transcriptional regulator

decreases expression

tolcapone results in decreased expression of NUPR2 mRNA

NCBI chr12:26,800,123...26,803,228
Ensembl chr12:26,799,800...26,803,304

G

prolyl 4-hydroxylase subunit alpha 1

affects binding

tolcapone binds to P4HA1 protein

NCBI chr20:27,302,046...27,352,098
Ensembl chr20:27,302,141...27,352,786

G

pyruvate carboxylase

affects binding

tolcapone binds to PC protein

NCBI chr 1:201,799,374...201,898,412
Ensembl chr 1:201,804,267...201,898,380

G

proliferating cell nuclear antigen

decreases expression

tolcapone results in decreased expression of PCNA mRNA

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

phosphate cytidylyltransferase 1A, choline

affects binding

tolcapone binds to PCYT1A protein

NCBI chr11:68,313,860...68,357,828
Ensembl chr11:68,313,882...68,357,357

G

PDZ domain containing 11

decreases expression

tolcapone results in decreased expression of PDZD11 mRNA

NCBI chr X:65,718,689...65,721,742
Ensembl chr X:65,704,067...65,721,642

G

prefoldin subunit 1

decreases expression

tolcapone results in decreased expression of PFDN1 mRNA

NCBI chr18:28,014,145...28,067,148
Ensembl chr18:28,014,145...28,067,064

G

prefoldin subunit 5

decreases expression

tolcapone results in decreased expression of PFDN5 mRNA

NCBI chr 7:133,451,778...133,456,516
Ensembl chr 7:133,451,453...133,456,516

G

phosphoglucomutase 1

increases expression

tolcapone results in increased expression of PGM1 mRNA

NCBI chr 5:114,595,298...114,654,728
Ensembl chr 5:114,595,293...114,654,728

G

progesterone receptor

multiple interactions

tolcapone binds to and results in decreased activity of PGR protein

NCBI chr 8:6,072,673...6,131,552
Ensembl chr 8:6,072,673...6,131,344

G

phosphatidylinositol glycan anchor biosynthesis, class P

decreases expression

tolcapone results in decreased expression of PIGP mRNA

NCBI chr11:33,682,943...33,689,111
Ensembl chr11:33,682,948...33,689,321

G

phosphatidylinositol glycan anchor biosynthesis, class S

affects binding

tolcapone binds to PIGS protein

NCBI chr10:63,222,611...63,237,190
Ensembl chr10:63,222,572...63,237,187

G

peptidylprolyl cis/trans isomerase, NIMA-interacting 4

decreases expression

tolcapone results in decreased expression of PIN4 mRNA

NCBI chr X:67,232,066...67,238,709
Ensembl chr X:67,232,081...67,238,702

G

perilipin 2

affects binding

tolcapone binds to PLIN2 protein

NCBI chr 5:101,156,648...101,211,738
Ensembl chr 5:101,154,411...101,242,319

G

perilipin 3

affects binding

tolcapone binds to PLIN3 protein

NCBI chr 9:1,111,178...1,123,057
Ensembl chr 9:1,102,366...1,123,147

G

patatin-like phospholipase domain containing 2

increases expression

tolcapone results in increased expression of PNPLA2 mRNA

NCBI chr 1:196,552,723...196,557,805
Ensembl chr 1:196,552,723...196,557,805

G

RNA polymerase I subunit H

decreases expression

Tolcapone results in decreased expression of POLR1H mRNA

NCBI chr20:1,594,936...1,598,854
Ensembl chr20:1,594,936...1,598,854

G

RNA polymerase II subunit G

decreases expression

tolcapone results in decreased expression of POLR2G mRNA

NCBI chr 1:205,689,160...205,692,537
Ensembl chr 1:205,689,160...205,692,686

G

pre-mRNA processing factor 8

affects binding

tolcapone binds to PRPF8 protein

NCBI chr10:60,331,494...60,354,606
Ensembl chr10:60,331,494...60,354,606

G

peroxiredoxin like 2A

affects binding

tolcapone binds to PRXL2A protein

NCBI chr16:16,866,601...16,886,378
Ensembl chr16:16,866,603...16,886,433

G

proteasome 26S subunit, ATPase 5

affects binding

tolcapone binds to PSMC5 protein

NCBI chr10:91,187,763...91,193,697
Ensembl chr10:91,187,743...91,213,135

G

proteasome activator subunit 2

affects binding

tolcapone binds to PSME2 protein

NCBI chr15:29,078,495...29,082,794
Ensembl chr15:29,078,500...29,082,946

G

prostaglandin-endoperoxide synthase 2

increases expression

Tolcapone results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

peptidyl-tRNA hydrolase 2

affects binding

tolcapone binds to PTRH2 protein

NCBI chr10:71,505,113...71,515,297
Ensembl chr10:71,504,956...71,515,398

G

RNA guanine-7 methyltransferase activating subunit

decreases expression

tolcapone results in decreased expression of RAMAC mRNA

NCBI chr 1:135,708,529...135,714,417
Ensembl chr 1:135,708,535...135,722,151

G

RAN, member RAS oncogene family

affects binding

tolcapone binds to RAN protein

NCBI chr12:27,674,049...27,678,598
Ensembl chr12:27,674,050...27,678,276